https://mpn-hub.com daily 1 2026-04-03T20:17:45.230Z https://mpn-hub.com/types weekly 0.8 2025-10-21T08:12:00.000Z https://mpn-hub.com/types/myeloproliferative-neoplasms weekly 0.7 2026-03-25T17:32:00.000Z https://mpn-hub.com/types/mpn-driver-mutations weekly 0.7 2025-03-06T11:32:00.000Z https://mpn-hub.com/types/risk weekly 0.7 2025-03-06T11:32:00.000Z https://mpn-hub.com/types/mpn-related-mutations weekly 0.7 2025-03-06T11:32:00.000Z https://mpn-hub.com/types/ph-negative-mpn weekly 0.7 2025-03-06T11:32:00.000Z https://mpn-hub.com/therapeutics weekly 0.8 2025-04-11T15:30:00.000Z https://mpn-hub.com/therapeutics/erythropoiesis-stimulating-agents weekly 0.7 2025-04-11T15:28:00.000Z https://mpn-hub.com/therapeutics/immune-modulators weekly 0.7 2025-04-11T15:28:00.000Z https://mpn-hub.com/therapeutics/hepcidin-mimetics weekly 0.7 2025-03-06T11:32:00.000Z https://mpn-hub.com/therapeutics/chemotherapy weekly 0.7 2025-04-11T15:28:00.000Z https://mpn-hub.com/therapeutics/bet-inhibitors weekly 0.7 2025-03-06T11:32:00.000Z https://mpn-hub.com/therapeutics/jak-inhibitors weekly 0.7 2025-07-08T14:31:00.000Z https://mpn-hub.com/therapeutics/activin-receptor-ligand-trap weekly 0.7 2025-03-06T11:32:00.000Z https://mpn-hub.com/therapeutics/kinase-inhibitors weekly 0.7 2025-04-11T15:28:00.000Z https://mpn-hub.com/therapeutics/telomerase-inhibitors weekly 0.7 2026-03-25T17:40:00.000Z https://mpn-hub.com/therapeutics/zilurgisertib weekly 0.7 2025-12-03T13:07:00.000Z https://mpn-hub.com/therapeutics/nivolumab weekly 0.7 2025-12-03T13:08:00.000Z https://mpn-hub.com/therapeutics/histone-modifiers weekly 0.7 2025-04-11T15:28:00.000Z https://mpn-hub.com/therapeutics/bcl-2-inhibitors weekly 0.7 2025-04-11T15:30:00.000Z https://mpn-hub.com/therapeutics/hypomethylating-agents weekly 0.7 2025-04-11T15:28:00.000Z https://mpn-hub.com/therapeutics/incb160058 weekly 0.7 2025-12-03T13:06:00.000Z https://mpn-hub.com/therapeutics/ropeginterferon-alfa-2b weekly 0.7 2025-12-03T13:06:00.000Z https://mpn-hub.com/therapeutics/opn-2853 weekly 0.7 2025-12-03T13:06:00.000Z https://mpn-hub.com/therapeutics/antibody-therapy weekly 0.7 2025-03-06T11:32:00.000Z https://mpn-hub.com/therapeutics/cellular-therapy weekly 0.7 2025-04-11T15:30:00.000Z https://mpn-hub.com/therapeutics/non-steroidal-anti-inflammatory-drugs weekly 0.7 2025-03-06T11:32:00.000Z https://mpn-hub.com/therapeutics/steroid weekly 0.7 2025-03-06T11:32:00.000Z https://mpn-hub.com/therapeutics/disc-0974 weekly 0.7 2025-10-13T13:07:00.000Z https://mpn-hub.com/therapeutics/inca035784 weekly 0.7 2025-07-31T08:07:00.000Z https://mpn-hub.com/therapeutics/sirna weekly 0.7 2025-07-15T08:41:00.000Z https://mpn-hub.com/therapeutics/phosphodiesterase-inhibitors weekly 0.7 2025-04-11T15:28:00.000Z https://mpn-hub.com/therapeutics/mdm2-inhibitors weekly 0.7 2025-03-06T11:32:00.000Z https://mpn-hub.com/therapeutics/antifibrotic-therapy weekly 0.7 2025-03-06T11:32:00.000Z https://mpn-hub.com/therapeutics/anticoagulants weekly 0.7 2025-04-11T15:30:00.000Z https://mpn-hub.com/therapeutics/pi3-kinase-inhibitors weekly 0.7 2025-04-11T15:28:00.000Z https://mpn-hub.com/therapeutics/nuclear-receptor-antagonists weekly 0.7 2025-03-06T11:32:00.000Z https://mpn-hub.com/therapeutics/smac-mimetics weekly 0.7 2025-03-06T11:32:00.000Z https://mpn-hub.com/therapeutics/car-t-cell-therapy weekly 0.7 2025-04-11T15:30:00.000Z https://mpn-hub.com/therapeutics/checkpoint-inhibitors weekly 0.7 2025-04-11T15:28:00.000Z https://mpn-hub.com/therapeutics/surgery weekly 0.7 2025-04-11T15:28:00.000Z https://mpn-hub.com/congresses weekly 0.8 2025-04-14T13:09:00.000Z https://mpn-hub.com/congresses/eha weekly 0.7 2025-07-03T10:00:00.000Z https://mpn-hub.com/congresses/soho weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/congresses/asco weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/congresses/esh-2025 weekly 0.7 2025-04-14T16:02:00.000Z https://mpn-hub.com/congresses/ebmt weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/congresses/iach weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/congresses/esh weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/congresses/ash weekly 0.7 2026-01-12T16:21:00.000Z https://mpn-hub.com/congresses/tct-meetings weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/congresses/other-events weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/congresses/mpncongress weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/congresses/mpncoandd weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/congresses/texas-mpn-workshop-1 weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/congresses/aacr weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials weekly 0.8 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/sentry-3 weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/simplify-2 weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/simplify-1 weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/momentum weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/rux-mf weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/odyssey weekly 0.7 2025-05-02T17:04:00.000Z https://mpn-hub.com/trials/revive weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/verify weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/thrive weekly 0.7 2025-12-03T13:04:00.000Z https://mpn-hub.com/trials/real-world-ernest-2-registry-study weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/infla-me weekly 0.7 2026-02-03T16:53:00.000Z https://mpn-hub.com/trials/mpn-fit weekly 0.7 2026-01-28T14:32:00.000Z https://mpn-hub.com/trials/promise weekly 0.7 2025-12-03T13:04:00.000Z https://mpn-hub.com/trials/restore weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/rop-et weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/inca033989-101 weekly 0.7 2025-12-23T09:19:00.000Z https://mpn-hub.com/trials/inca033989-102 weekly 0.7 2025-12-23T09:19:00.000Z https://mpn-hub.com/trials/persist-2 weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/persist-1 weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/manifest-2 weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/improvemf weekly 0.7 2025-07-05T10:34:00.000Z https://mpn-hub.com/trials/famy weekly 0.7 2025-12-03T13:04:00.000Z https://mpn-hub.com/trials/fraction weekly 0.7 2025-12-03T13:05:00.000Z https://mpn-hub.com/trials/shorespan-004 weekly 0.7 2025-12-03T13:03:00.000Z https://mpn-hub.com/trials/ropeg-pv weekly 0.7 2025-12-03T13:04:00.000Z https://mpn-hub.com/trials/pathfinder weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/summit weekly 0.7 2025-12-03T13:02:00.000Z https://mpn-hub.com/trials/inca33989-101 weekly 0.7 2025-07-24T08:15:00.000Z https://mpn-hub.com/trials/inca33989-102 weekly 0.7 2025-07-24T08:15:00.000Z https://mpn-hub.com/trials/comfort-ii weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/comfort-i weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/jump weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/transform-1 weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/limber weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/jakomo weekly 0.7 2025-09-16T15:34:00.000Z https://mpn-hub.com/trials/pacific weekly 0.7 2025-11-26T15:23:00.000Z https://mpn-hub.com/trials/ramp-study weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/independence weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/jakarta weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/jakarta2 weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/pac203 weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/nct03731260 weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/impactmf weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/surpass-et weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/low-pv weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/ace-536-mf-001 weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/p1101mf weekly 0.7 2025-07-18T08:04:00.000Z https://mpn-hub.com/trials/sanreco weekly 0.7 2025-07-15T08:41:00.000Z https://mpn-hub.com/trials/giv-in-pv weekly 0.7 2025-05-08T11:46:00.000Z https://mpn-hub.com/trials/freedom weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/freedom2 weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/response weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/response-2 weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/relief weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/majic-et weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/majic-pv weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/meter weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/zgjak016 weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/paradigm-pv weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/apex weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/pv-arc weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/exceed-et weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/krt-232-101 weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/combi-ii weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/ares weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/proud-pv weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/continuation-pv weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/sentry-2 weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/reveal weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/zgjak002 weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/nct01387763 weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/majic weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/manifest weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/nct03222609 weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/krt-232-109 weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/ruxobeat weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/ruxopeg weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/imbark weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/ship weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/eclap weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/zgjak017 weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/zgjak006 weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/expand weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/essential-thrombocytosis-1 weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/irene-g weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/mysec weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/mascot weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/realism-uk weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/nct03011372 weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/explorer weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/peginvera weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/epicovideha weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/mpn-covid weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/combi weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/mithridate weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/resume weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/trials/incb-18424-261 weekly 0.7 2025-04-14T13:09:00.000Z https://mpn-hub.com/expert-opinions weekly 0.8 2025-04-16T08:52:00.000Z https://mpn-hub.com/drug-updates weekly 0.8 2025-04-16T08:52:00.000Z https://mpn-hub.com/educational-resources weekly 0.8 2025-12-19T12:36:00.000Z https://mpn-hub.com/educational-resources/spotlights weekly 0.7 2025-12-19T14:35:00.000Z https://mpn-hub.com/educational-resources/masterclass weekly 0.7 2025-12-19T12:36:00.000Z https://mpn-hub.com/educational-resources/thrombosis weekly 0.7 2025-10-13T10:42:00.000Z https://mpn-hub.com/educational-resources/ai-1 weekly 0.7 2025-04-14T15:54:00.000Z https://mpn-hub.com/educational-resources/steering-committee-meetings weekly 0.7 2025-12-19T12:36:00.000Z https://mpn-hub.com/educational-resources/anemia-in-patients-with-myelofibrosis weekly 0.7 2025-12-19T14:35:00.000Z https://mpn-hub.com/educational-resources/treatment-sequencing weekly 0.7 2025-04-14T15:54:00.000Z https://mpn-hub.com/educational-resources/mpn-hub-symposiums weekly 0.7 2025-12-19T12:36:00.000Z https://mpn-hub.com/educational-resources/visual-abstracts weekly 0.7 2025-12-19T12:36:00.000Z https://mpn-hub.com/educational-resources/special-populations weekly 0.7 2025-04-14T15:54:00.000Z https://mpn-hub.com/educational-resources/mpn-hub-ctcs weekly 0.7 2025-12-19T12:40:00.000Z https://mpn-hub.com/educational-resources/drug-timelines weekly 0.7 2025-04-14T15:54:00.000Z https://mpn-hub.com/educational-resources/disease-overviews weekly 0.7 2025-12-19T12:36:00.000Z https://mpn-hub.com/educational-resources/combination-therapies weekly 0.7 2025-04-14T15:54:00.000Z https://mpn-hub.com/educational-resources/guidelines weekly 0.7 2025-04-14T15:54:00.000Z https://mpn-hub.com/educational-resources/toxicity-management weekly 0.7 2025-04-14T15:54:00.000Z https://mpn-hub.com/medical-information/ruxolitinib-in-mf-with-anemia-real-world-treatment-patterns-and-survival-outcomes monthly 0.9 2026-04-02T08:32:00.000Z https://mpn-hub.com/medical-information/sentry-phase-i-selinexor-ruxolitinib-in-mf monthly 0.9 2026-03-31T08:48:00.000Z https://mpn-hub.com/medical-information/overall-survival-with-momelotinib-vs-bat-in-ruxolitinib-experienced-mf monthly 0.9 2026-03-27T10:00:00.000Z https://mpn-hub.com/medical-information/rux-mf-real-world-study-subanalysis-prognostic-impact-of-cytopenia-in-mf-treated-with-ruxolitinib monthly 0.9 2026-03-24T10:00:00.000Z https://mpn-hub.com/medical-information/amlmds-transformation-risk-in-mpn-impact-of-attained-age-and-disease-duration monthly 0.9 2026-03-20T10:00:00.000Z https://mpn-hub.com/medical-information/ai-assisted-differentiation-of-prefibrotic-pmf-and-et monthly 0.9 2026-03-17T09:48:00.000Z https://mpn-hub.com/medical-information/pros-of-complementary-and-alternative-medicine-in-bcrabl1-negative-mpn monthly 0.9 2026-03-13T07:00:00.000Z https://mpn-hub.com/medical-information/the-phase-ii-odyssey-trial-momelotinib-luspatercept-in-td-mf monthly 0.9 2026-03-12T09:09:00.000Z https://mpn-hub.com/medical-information/ropeginterferon-alfa2b-in-pregnant-and-lactating-patients-with-mpn monthly 0.9 2026-03-10T14:07:00.000Z https://mpn-hub.com/medical-information/fda-accepted-nda-and-granted-priority-review-for-rusfertide-in-pv monthly 0.9 2026-03-06T15:00:00.000Z https://mpn-hub.com/medical-information/clinical-characteristics-and-driver-mutations-in-patients-with-et-jak2v617f-andor-calr-mutations monthly 0.9 2026-03-06T09:36:00.000Z https://mpn-hub.com/medical-information/iron-parameters-and-jak2-vaf-as-diagnostic-markers-for-pv-and-et monthly 0.9 2026-03-03T10:00:00.000Z https://mpn-hub.com/medical-information/ernest-2-retrospective-validation-prognostic-value-of-anemia-thrombocytopenia-in-primary-mf monthly 0.9 2026-02-27T09:00:00.000Z https://mpn-hub.com/medical-information/long-term-ropeginterferon-alfa2b-hidat-treatment-in-pv-phase-ii-results monthly 0.9 2026-02-24T10:00:00.000Z https://mpn-hub.com/medical-information/predictive-value-of-nlr-for-thrombotic-risk-in-prefibrotic-primary-mf-infla-me-sub-analysis monthly 0.9 2026-02-20T10:00:00.000Z https://mpn-hub.com/medical-information/impact-of-sf3b1-mutation-on-luspatercept-efficacy-in-anemic-mpn-or-mdsmpn monthly 0.9 2026-02-17T10:00:00.000Z https://mpn-hub.com/medical-information/impact-of-statins-on-cardiovascular-and-hematologic-outcomes-in-mpn monthly 0.9 2026-02-13T09:00:00.000Z https://mpn-hub.com/medical-information/mpn-fit-exercise-interventions-for-mpn monthly 0.9 2026-02-10T09:00:00.000Z https://mpn-hub.com/medical-information/treatment-patterns-and-outcomes-in-pv-and-et-a-nationwide-study monthly 0.9 2026-02-06T09:00:00.000Z https://mpn-hub.com/medical-information/momelotinib-in-jaki-naive-mf-real-world-findings monthly 0.9 2026-02-04T17:00:00.000Z https://mpn-hub.com/medical-information/triple-negative-primary-mf-a-comparative-analysis-of-phenotype-genotype-and-outcomes monthly 0.9 2026-01-30T10:00:00.000Z https://mpn-hub.com/medical-information/ruxolitinib-long-term-safety-in-chronic-mpn-real-world-data monthly 0.9 2026-01-26T11:00:00.000Z https://mpn-hub.com/medical-information/zavabresib-granted-fda-orphan-drug-designation-for-the-treatment-of-mf monthly 0.9 2026-01-22T16:00:00.000Z https://mpn-hub.com/medical-information/cmwp-ebmt-european-survey-on-allo-hsct-practices-for-mf monthly 0.9 2026-01-21T10:36:00.000Z https://mpn-hub.com/medical-information/ropeginterferon-alfa-2b-real-world-outcomes-in-patients-with-ph-mpn monthly 0.9 2026-01-19T10:44:00.000Z https://mpn-hub.com/medical-information/momelotinib-efficacy-and-safety-in-mf-retrospective-real-world-data monthly 0.9 2026-01-16T12:01:00.000Z https://mpn-hub.com/medical-information/thrive-phase-ii-extension-long-term-rusfertide-treatment-in-pv monthly 0.9 2026-01-14T11:54:00.000Z https://mpn-hub.com/medical-information/restore-phase-ii-updated-results-elritercept-in-mf monthly 0.9 2026-01-09T10:11:00.000Z https://mpn-hub.com/medical-information/allogeneic-t-reg-therapy-ck0804-granted-fda-orphan-drug-designation-for-the-treatment-of-mf monthly 0.9 2026-01-08T09:01:00.000Z https://mpn-hub.com/medical-information/rop-et-phase-iii-preliminary-results-ropeginterferon-alfa-2b-for-et monthly 0.9 2026-01-09T10:12:00.000Z https://mpn-hub.com/medical-information/phase-i-trials-inca033989-ruxolitinib-for-myelofibrosis monthly 0.9 2026-01-05T09:18:00.000Z https://mpn-hub.com/medical-information/simplify-1-and-momentum-trials-impact-of-hb-improvement-on-os-with-momelotinib monthly 0.9 2025-12-29T12:00:00.000Z https://mpn-hub.com/medical-information/odyssey-phase-ii-preliminary-results-momelotinib-luspatercept-in-td-mf monthly 0.9 2025-12-23T12:00:00.000Z https://mpn-hub.com/medical-information/ash-2025-congress-coverage-myelofibrosis monthly 0.9 2025-12-16T08:43:00.000Z https://mpn-hub.com/medical-information/ash-2025-congress-coverage-polycythemia-vera monthly 0.9 2025-12-16T08:43:00.000Z https://mpn-hub.com/medical-information/ash-2025-congress-coverage-other-mpn monthly 0.9 2025-12-16T08:41:00.000Z https://mpn-hub.com/medical-information/ash-2025-nuvisertib-momelotinib-in-patients-with-rr-mf-phase-iii-findings monthly 0.9 2025-12-17T14:58:00.000Z https://mpn-hub.com/medical-information/inca033989-granted-breakthrough-therapy-designation-by-the-fda-for-et monthly 0.9 2025-12-11T15:00:00.000Z https://mpn-hub.com/medical-information/ash-2025-what-are-the-key-findings-from-the-12-month-primary-endpoint-analysis-of-the-rop-et-phase-iii-study monthly 0.9 2025-12-15T21:45:00.000Z https://mpn-hub.com/medical-information/ash-2025-top-abstracts-whats-hot-in-mpn monthly 0.9 2025-12-03T17:38:00.000Z https://mpn-hub.com/medical-information/phase-iii-trial-tagraxofusp-in-myelofibrosis monthly 0.9 2025-12-04T11:03:00.000Z https://mpn-hub.com/medical-information/mpn-hub-spotlight-ruxolitinib-for-mf monthly 0.9 2025-12-19T14:32:00.000Z https://mpn-hub.com/medical-information/pacific-phase-ii-final-results-rusfertide-in-pv monthly 0.9 2025-11-28T11:40:00.000Z https://mpn-hub.com/medical-information/tci-score-for-prediction-of-allo-hsct-outcomes-in-myelofibrosis monthly 0.9 2025-11-21T12:58:00.000Z https://mpn-hub.com/medical-information/defining-disease-progression-in-pv-a-us-modified-delphi-consensus monthly 0.9 2025-11-18T10:00:00.000Z https://mpn-hub.com/medical-information/ob756-in-et-results-from-a-phase-ii-trial monthly 0.9 2025-11-14T14:39:00.000Z https://mpn-hub.com/medical-information/how-might-extended-release-formulations-of-ruxolitinib-benefit-patients-with-mf monthly 0.9 2025-11-11T14:08:00.000Z https://mpn-hub.com/medical-information/rovadicitinib-in-mf-results-of-a-phase-ib-trial monthly 0.9 2025-11-07T12:00:00.000Z https://mpn-hub.com/medical-information/pxs-5505-in-advanced-mf-results-of-a-phase-iiia-trial monthly 0.9 2025-10-31T15:00:00.000Z https://mpn-hub.com/medical-information/masterclass-navigating-the-evolving-treatment-landscape-for-mf-related-anemia monthly 0.9 2025-10-31T15:36:00.000Z https://mpn-hub.com/medical-information/fedratinib-exposure-response-in-mf-pooled-phase-iiiii-data monthly 0.9 2025-12-11T10:20:00.000Z https://mpn-hub.com/medical-information/real-world-ruxolitinib-in-mf-a-multicenter-japanese-study monthly 0.9 2025-10-24T10:00:00.000Z https://mpn-hub.com/medical-information/qrisk3-score-predicts-thrombotic-risk-in-myeloproliferative-neoplasms monthly 0.9 2025-10-22T09:00:00.000Z https://mpn-hub.com/medical-information/what-is-on-the-horizon-for-the-treatment-of-myelofibrosis-related-anemia monthly 0.9 2025-10-29T14:01:00.000Z https://mpn-hub.com/medical-information/machine-learning-algorithms-to-diagnose-pv monthly 0.9 2025-10-08T13:18:00.000Z https://mpn-hub.com/medical-information/momelotinib-in-mf-a-real-world-study-of-immune-cell-recovery monthly 0.9 2025-10-14T14:34:00.000Z https://mpn-hub.com/medical-information/limber-safety-and-tolerability-of-incb057643-in-patients-with-mf-and-other-advanced-mpn monthly 0.9 2025-10-31T15:37:00.000Z https://mpn-hub.com/medical-information/iach-2025-live-congress-coverage-from-the-mpn-hub monthly 0.9 2025-10-14T14:22:00.000Z https://mpn-hub.com/medical-information/what-are-the-unmet-needs-in-the-management-of-myelofibrosis-related-anemia monthly 0.9 2025-10-29T14:01:00.000Z https://mpn-hub.com/medical-information/metabolomic-profiling-distinguishes-primary-from-secondary-polycythemia monthly 0.9 2025-10-07T17:51:00.000Z https://mpn-hub.com/medical-information/low-dose-ropeginterferon-alfa-2b-vs-peginterferon-alfa-2a-in-pv monthly 0.9 2025-10-03T12:27:00.000Z https://mpn-hub.com/medical-information/real-world-momelotinib-in-myelofibrosis-a-multicenter-italian-study monthly 0.9 2025-10-01T15:21:00.000Z https://mpn-hub.com/medical-information/how-i-treat-myelofibrosis-related-anemia monthly 0.9 2025-10-30T15:55:00.000Z https://mpn-hub.com/medical-information/impact-of-age-and-time-since-diagnosis-on-thrombosis-risk-in-mpn-a-swedish-matched-cohort-study monthly 0.9 2025-09-18T12:56:00.000Z https://mpn-hub.com/medical-information/ai-based-quantitative-bone-marrow-pathology-analysis-for-mpn monthly 0.9 2025-09-18T13:24:00.000Z https://mpn-hub.com/medical-information/ruxolitinib-for-the-treatment-of-mf-in-clinical-routine-initial-results-from-a-phase-iv-study monthly 0.9 2025-09-19T09:09:00.000Z https://mpn-hub.com/medical-information/momelotinib-vs-fedratinib-safety-outcomes-in-patients-with-mf-an-indirect-treatment-comparison monthly 0.9 2025-09-15T14:10:00.000Z https://mpn-hub.com/medical-information/momelotinib-vs-pacritinib-safety-and-anemia-outcomes-in-patients-with-mf-an-indirect-treatment-comparison monthly 0.9 2025-09-11T19:34:00.000Z https://mpn-hub.com/medical-information/efficacy-and-safety-of-nuvisertib-in-mf-preliminary-phase-iii-data monthly 0.9 2025-09-04T10:44:00.000Z https://mpn-hub.com/medical-information/soho-2025-live-congress-feed monthly 0.9 2025-09-08T16:24:00.000Z https://mpn-hub.com/medical-information/vgt-1849b-granted-orphan-drug-designation-by-the-fda-for-pv monthly 0.9 2025-09-03T09:58:00.000Z https://mpn-hub.com/medical-information/jump-trial-a-post-hoc-analysis-of-ruxolitinib-and-anemia-supporting-medications-in-patients-with-mf monthly 0.9 2025-08-26T13:47:00.000Z https://mpn-hub.com/medical-information/rusfertide-granted-breakthrough-therapy-designation-by-the-fda-for-erythrocytosis-in-pv monthly 0.9 2025-08-26T13:50:00.000Z https://mpn-hub.com/medical-information/low-pv-trial-long-term-outcomes-with-low-dose-ropeginterferon-alpha-2b-in-patients-with-low-risk-pv monthly 0.9 2025-08-21T13:45:00.000Z https://mpn-hub.com/medical-information/pelabresib-ruxolitinib-in-jaki-naive-patients-latest-clinical-trial-data monthly 0.9 2025-08-22T11:37:00.000Z https://mpn-hub.com/medical-information/novel-targeted-therapies-for-rr-mf-pim1-kinase-inhibition monthly 0.9 2025-09-03T09:04:00.000Z https://mpn-hub.com/medical-information/impact-of-luspatercept-on-hb-and-qol-in-non-transfusion-dependent-mf-a-post-hoc-analysis-of-ace-536-mf-001 monthly 0.9 2025-08-13T07:37:00.000Z https://mpn-hub.com/medical-information/inca035784-a-novel-t-cell-redirecting-antibody-for-calr-mutations-in-mpn monthly 0.9 2025-08-04T09:27:00.000Z https://mpn-hub.com/medical-information/nuvisertib-granted-orphan-drug-designation-by-the-ema-for-mf monthly 0.9 2025-07-31T11:39:00.000Z https://mpn-hub.com/medical-information/inca33989-a-first-in-class-mutant-calr-specific-monoclonal-antibody-for-et-phase-i-results monthly 0.9 2025-07-24T09:16:00.000Z https://mpn-hub.com/medical-information/p1101mf-phase-ii-results-ropeginterferon-alfa-2b-in-patients-with-early-or-lower-risk-mf monthly 0.9 2025-07-18T09:02:00.000Z https://mpn-hub.com/medical-information/sanreco-phase-i-results-divesiran-a-first-in-class-sirna-in-patients-with-pv monthly 0.9 2025-07-18T07:54:00.000Z https://mpn-hub.com/medical-information/manifest-2-long-term-follow-up-results-pelabresib-ruxolitinib-in-jaki-naive-patients-with-mf monthly 0.9 2025-07-10T17:11:00.000Z https://mpn-hub.com/medical-information/improvemf-update-imetelstat-plus-ruxolitinib-in-patients-with-mf monthly 0.9 2025-07-08T10:23:00.000Z https://mpn-hub.com/medical-information/surpass-et-topline-results-ropeginterferon-alfa-2b-vs-anagrelide-for-et monthly 0.9 2025-07-03T15:47:00.000Z https://mpn-hub.com/medical-information/verify-phase-iii-part-1a-rusfertide-vs-placebo-for-phlebotomy-dependent-pv monthly 0.9 2025-06-19T20:53:00.000Z https://mpn-hub.com/medical-information/how-i-treat-patients-with-low-risk-pv-requiring-cytoreduction monthly 0.9 2025-06-23T10:02:00.000Z https://mpn-hub.com/medical-information/simplify-1-and-momentum-post-hoc-analyses-survival-impact-of-hemoglobin-improvement-with-momelotinib-in-mf-with-moderate-to-severe-anemia monthly 0.9 2025-06-23T09:18:00.000Z https://mpn-hub.com/medical-information/simplify-1-subgroup-analysis-survival-impact-of-dual-spleen-response-and-transfusion-independence-in-jaki-naive-patients-with-mf-and-anemia-treated-with-momelotinib monthly 0.9 2025-06-23T09:17:00.000Z https://mpn-hub.com/medical-information/fda-grants-fast-track-designation-to-nuvisertib-for-the-treatment-of-myelofibrosis monthly 0.9 2025-06-18T09:50:00.000Z https://mpn-hub.com/medical-information/eha-2025-congress-coverage monthly 0.9 2025-06-30T12:09:00.000Z https://mpn-hub.com/medical-information/eha-2025-abstracts-whats-hot-in-mpn monthly 0.9 2025-06-09T15:14:00.000Z https://mpn-hub.com/medical-information/ruxolitinib-for-the-treatment-of-mf-case-based-recommendations-for-adverse-event-management monthly 0.9 2025-06-05T10:17:00.000Z https://mpn-hub.com/medical-information/2025-asco-annual-meeting-congress-coverage monthly 0.9 2025-06-04T15:53:00.000Z https://mpn-hub.com/medical-information/transplant-outcomes-with-alternative-donors-in-mf-a-japanese-registry-analysis monthly 0.9 2025-06-03T09:05:00.000Z https://mpn-hub.com/medical-information/mpn-symptom-burden-a-real-world-cohort-study-from-quebec monthly 0.9 2025-05-22T14:08:00.000Z https://mpn-hub.com/medical-information/a-toolkit-for-healthcare-transition-in-adolescents-with-mpn monthly 0.9 2025-05-22T15:56:00.000Z https://mpn-hub.com/medical-information/factors-influencing-delays-in-mpn-presentation-and-diagnosis-a-cross-sectional-study monthly 0.9 2025-06-25T11:58:00.000Z https://mpn-hub.com/medical-information/busulphan-efficacy-and-safety-based-on-real-world-dosing-patterns-in-mpn-management monthly 0.9 2025-05-19T08:34:00.000Z https://mpn-hub.com/medical-information/romei-interim-analysis-from-a-real-world-study-of-ruxolitinib-in-patients-with-mf monthly 0.9 2025-05-12T09:29:00.000Z https://mpn-hub.com/medical-information/momgemfin-real-world-study-of-momelotinib-in-patients-with-mf-and-anemia monthly 0.9 2025-05-08T16:21:00.000Z https://mpn-hub.com/medical-information/fda-grants-fast-track-designation-to-givinostat-for-polycythemia-vera monthly 0.9 2025-05-08T12:41:00.000Z https://mpn-hub.com/medical-information/novel-treatments-momelotinib-and-luspatercept monthly 0.9 2025-05-19T14:31:00.000Z https://mpn-hub.com/medical-information/anemia-as-an-unmet-need-impacts-on-qol-and-survival-outcomes monthly 0.9 2025-05-15T12:57:00.000Z https://mpn-hub.com/medical-information/impact-of-treatment-on-thrombotic-complications-in-aya-with-et-and-pv-a-retrospective-analysis monthly 0.9 2025-04-24T13:57:00.000Z https://mpn-hub.com/medical-information/symposium-or-anemia-in-myelofibrosis-qanda monthly 0.9 2025-05-12T13:59:00.000Z https://mpn-hub.com/medical-information/symposium-sequencing-therapies-optimizing-treatment-for-myelofibrosis monthly 0.9 2025-05-08T12:28:00.000Z https://mpn-hub.com/medical-information/symposium-or-the-treatment-landscape-for-patients-with-myelofibrosis-and-anemia monthly 0.9 2025-05-07T15:46:00.000Z https://mpn-hub.com/medical-information/symposium-or-anemia-in-myelofibrosis-impact-on-patient-outcomes monthly 0.9 2025-05-06T13:21:00.000Z https://mpn-hub.com/medical-information/51st-annual-meeting-of-the-ebmt-2025-congress-coverage monthly 0.9 2025-04-14T10:12:00.000Z https://mpn-hub.com/medical-information/treatment-patterns-and-healthcare-resource-utilization-in-ruxolitinib-treated-patients-with-mf-stratified-by-anemia-status-a-real-world-analysis monthly 0.9 2025-04-11T09:45:00.000Z https://mpn-hub.com/medical-information/mpn-hub-spotlight-the-rop-et-trial-of-ropeginterferon-alfa-2b-in-patients-with-et-and-limited-treatment-options monthly 0.9 2025-12-19T14:34:00.000Z https://mpn-hub.com/medical-information/manifest-2-primary-analysis-of-pelabresib-plus-ruxolitinib-in-jaki-naive-patients-with-mf monthly 0.9 2025-04-03T12:49:00.000Z https://mpn-hub.com/medical-information/transfusion-intensity-in-patients-with-jaki-naive-or-jaki-exposed-mf-treated-with-momelotinib-a-longitudinal-assessment monthly 0.9 2025-05-01T12:54:00.000Z https://mpn-hub.com/medical-information/visual-abstract-or-freedom2-fedratinib-vs-bat-in-in-patients-with-mf-previously-treated-with-ruxolitinib monthly 0.9 2025-03-26T11:06:00.000Z https://mpn-hub.com/medical-information/cardiovascular-safety-of-jak-inhibitors-in-mpn-a-first-of-a-kind-meta-analysis monthly 0.9 2025-03-21T10:59:00.000Z https://mpn-hub.com/medical-information/patient-vs-physician-reported-symptom-burden-in-mpn-a-gsg-mpn-intraindividual-analysis monthly 0.9 2025-03-17T17:38:00.000Z https://mpn-hub.com/medical-information/the-role-of-molecular-risk-in-predicting-survival-benefit-and-guiding-transplant-decisions-in-primary-mf monthly 0.9 2025-03-13T12:45:00.000Z https://mpn-hub.com/medical-information/prognostic-impact-of-tp53-mutations-in-patients-with-mpn monthly 0.9 2025-03-11T14:40:00.000Z https://mpn-hub.com/medical-information/impact-of-calr-mutations-in-patients-with-mf-treated-with-ruxolitinib monthly 0.9 2025-03-06T15:48:00.000Z https://mpn-hub.com/medical-information/phase-iii-verify-trial-of-rusfertide-in-patients-with-pv-positive-topline-results-announced monthly 0.9 2025-03-06T14:19:00.000Z https://mpn-hub.com/medical-information/sentry-a-phase-iii-study-of-selinexor-in-combination-with-ruxolitinib-for-jaki-naive-mf monthly 0.9 2025-03-03T16:44:00.000Z https://mpn-hub.com/medical-information/underutilization-of-cytoreductive-therapies-for-pv-a-german-observational-study monthly 0.9 2025-02-26T12:23:00.000Z https://mpn-hub.com/medical-information/clinical-and-immunological-effects-of-peri-transplantation-jak-inhibition-for-mf monthly 0.9 2025-02-24T10:13:00.000Z https://mpn-hub.com/medical-information/real-world-ernest-2-registry-study-clinical-characteristics-and-outcomes-in-patients-with-overt-primary-mf-and-cytopenias monthly 0.9 2025-02-20T14:54:00.000Z https://mpn-hub.com/medical-information/meter-study-real-world-treatment-patterns-in-patients-with-mf monthly 0.9 2025-02-19T11:10:00.000Z https://mpn-hub.com/medical-information/jaktinib-for-patients-with-mf-final-results-from-the-phase-iii-zgjak016-trial monthly 0.9 2025-02-13T10:56:00.000Z https://mpn-hub.com/medical-information/clinical-trial-round-up-treating-anemia-in-patients-with-myelofibrosis monthly 0.9 2025-03-26T11:16:00.000Z https://mpn-hub.com/medical-information/revive-phase-ii-final-results-rusfertide-in-patients-with-polycythemia-vera monthly 0.9 2025-02-06T10:42:00.000Z https://mpn-hub.com/medical-information/managing-anemia-in-patients-with-mf-unmet-needs-and-therapeutic-options monthly 0.9 2026-03-04T14:14:00.000Z https://mpn-hub.com/medical-information/paradigm-pv-ropeginterferon-alfa-2b-in-patients-with-low-or-high-risk-polycythemia-vera monthly 0.9 2025-01-30T15:11:00.000Z https://mpn-hub.com/medical-information/restore-phase-ii-results-elritercept-as-monotherapy-and-in-combination-with-ruxolitinib-in-mf monthly 0.9 2025-01-27T09:37:00.000Z https://mpn-hub.com/medical-information/apex-part-i-bezuclastinib-for-advsm monthly 0.9 2025-01-23T17:40:00.000Z https://mpn-hub.com/medical-information/mpn-hub-spotlight-momelotinib-mechanism-of-action monthly 0.9 2025-12-19T14:33:00.000Z https://mpn-hub.com/medical-information/momelotinib-vs-bat-for-patients-with-mf-previously-treated-with-ruxolitinib-a-matching-adjusted-indirect-comparison monthly 0.9 2025-05-01T12:56:00.000Z https://mpn-hub.com/medical-information/manifest-2-updated-results-pelabresib-plus-ruxolitinib-in-jaki-naive-patients-with-mf monthly 0.9 2025-01-22T13:59:00.000Z https://mpn-hub.com/medical-information/pv-arc-eln-clinical-signs-and-symptoms-for-thrombotic-risk-in-patients-with-pv-treated-with-hu monthly 0.9 2025-01-08T15:34:00.000Z https://mpn-hub.com/medical-information/surpass-et-trial-of-ropeginterferon-alfa-2b-in-patients-with-et-positive-topline-data-announced monthly 0.9 2025-01-08T14:32:00.000Z https://mpn-hub.com/medical-information/fedratinib-in-patients-with-mf-with-low-or-high-baseline-platelet-count-a-subanalysis-of-the-phase-iii-freedom2-trial monthly 0.9 2025-01-07T15:15:00.000Z https://mpn-hub.com/medical-information/boreas-efficacy-and-safety-of-navtemadlin-in-jaki-rr-mf monthly 0.9 2025-03-12T15:34:00.000Z https://mpn-hub.com/medical-information/2024-ash-annual-meeting-live-congress-feed monthly 0.9 2024-12-16T12:11:00.000Z https://mpn-hub.com/medical-information/risk-factors-for-hemorrhagic-events-in-patients-with-polycythemia-vera monthly 0.9 2024-12-09T12:36:00.000Z https://mpn-hub.com/medical-information/ash-2024-abstracts-what-s-hot-in-mpn monthly 0.9 2024-12-05T09:48:00.000Z https://mpn-hub.com/medical-information/treatment-of-thrombotic-complications-in-patients-with-mpn monthly 0.9 2024-11-28T15:16:00.000Z https://mpn-hub.com/medical-information/impact-of-a-reduced-starting-dose-of-ruxolitinib-on-survival-in-patients-with-mf monthly 0.9 2024-12-04T11:44:00.000Z https://mpn-hub.com/medical-information/prevention-and-treatment-of-acceleratedblast-phase-myeloproliferative-neoplasms monthly 0.9 2024-11-20T12:49:00.000Z https://mpn-hub.com/medical-information/momelotinib-for-the-treatment-of-mf-long-term-data monthly 0.9 2025-05-01T12:56:00.000Z https://mpn-hub.com/medical-information/mpn-risk-scoring-current-algorithms-for-clinical-practice monthly 0.9 2024-11-15T10:31:00.000Z https://mpn-hub.com/medical-information/allo-hsct-for-elderly-patients-with-mf-results-from-the-german-registry-for-stem-cell-transplantation-study monthly 0.9 2024-11-11T14:51:00.000Z https://mpn-hub.com/medical-information/momelotinib-impact-on-transfusion-dependence-and-qol-in-mf monthly 0.9 2024-11-05T10:52:00.000Z https://mpn-hub.com/medical-information/freedom-2-primary-analysis-of-the-efficacy-and-safety-of-fedratinib-in-mf monthly 0.9 2024-11-04T14:58:00.000Z https://mpn-hub.com/medical-information/jak-inhibitors-for-mf-individualizing-treatment-selection monthly 0.9 2024-10-24T12:57:00.000Z https://mpn-hub.com/medical-information/risk-factors-associated-with-high-risk-patients-with-pv-an-update-from-iach-2024 monthly 0.9 2024-10-23T10:42:00.000Z https://mpn-hub.com/medical-information/treatments-for-systemic-mastocytosis-latest-updates-from-iach monthly 0.9 2024-10-16T12:33:00.000Z https://mpn-hub.com/medical-information/recommendations-for-managing-mf-with-a-focus-on-patients-with-cytopenias-from-the-global-consensus-group monthly 0.9 2024-10-15T16:27:00.000Z https://mpn-hub.com/medical-information/jak-inhibitors-for-the-treatment-of-mf-latest-updates-from-iach monthly 0.9 2024-10-10T12:17:00.000Z https://mpn-hub.com/medical-information/jak2-v617f-mutation-in-mpn-pathogenesis-insights-and-potential-therapeutic-implications monthly 0.9 2024-10-08T16:04:00.000Z https://mpn-hub.com/medical-information/luspatercept-for-the-treatment-of-myelofibrosis-with-anemia-latest-data-from-ace-536-mf-001 monthly 0.9 2024-10-03T16:37:00.000Z https://mpn-hub.com/medical-information/peg-ifn-plus-ruxolitinib-in-newly-diagnosed-patients-with-pv-results-from-the-combi-ii-trial monthly 0.9 2024-09-27T09:11:00.000Z https://mpn-hub.com/medical-information/iach-2024-live-congress-feed monthly 0.9 2024-09-27T13:06:00.000Z https://mpn-hub.com/medical-information/ropeginterferon-alfa-2b-in-patients-with-earlylower-risk-primary-mf monthly 0.9 2024-09-20T08:37:00.000Z https://mpn-hub.com/medical-information/momelotinib-in-patients-with-mf-and-anemia-subgroup-analysis-of-the-simplify-2-trial monthly 0.9 2024-09-19T14:47:00.000Z https://mpn-hub.com/medical-information/impact-of-donor-type-on-transplant-outcomes-in-patients-with-mf monthly 0.9 2024-09-12T13:24:00.000Z https://mpn-hub.com/medical-information/machine-learning-based-quantitative-analysis-of-bone-marrow-fibrosis-in-patients-with-mf monthly 0.9 2024-09-06T14:21:00.000Z https://mpn-hub.com/medical-information/aspirin-therapy-and-risk-of-pregnancy-loss-in-patients-with-et monthly 0.9 2024-09-03T15:07:00.000Z https://mpn-hub.com/medical-information/soho-2024-live-congress-feed monthly 0.9 2024-09-16T12:42:00.000Z https://mpn-hub.com/medical-information/prophylactic-gvhd-treatment-with-atlg-in-patients-with-myelofibrosis monthly 0.9 2024-08-29T14:41:00.000Z https://mpn-hub.com/medical-information/sex-specific-impact-on-clinical-outcomes-in-patients-with-et monthly 0.9 2024-08-29T08:11:00.000Z https://mpn-hub.com/medical-information/twice-daily-vs-once-daily-low-dose-aspirin-for-et-results-from-the-ares-trial monthly 0.9 2024-08-23T12:48:00.000Z https://mpn-hub.com/medical-information/momelotinib-vs-ruxolitinib-in-patients-with-mf-by-baseline-hemoglobin-levels-exploratory-post-hoc-analysis-from-simplify-1 monthly 0.9 2024-08-21T16:07:00.000Z https://mpn-hub.com/medical-information/impact-of-mutated-jak2-allele-burden-on-the-outcomes-in-pv-and-et monthly 0.9 2024-08-14T11:21:00.000Z https://mpn-hub.com/medical-information/what-more-can-be-done-to-improve-treatment-for-patients-with-polycythemia-vera monthly 0.9 2024-08-13T09:53:00.000Z https://mpn-hub.com/medical-information/ropeginterferon-alfa2b-real-world-data-for-the-treatment-of-pv monthly 0.9 2024-07-31T19:21:00.000Z https://mpn-hub.com/medical-information/meaningful-biomarkers-in-myeloproliferative-neoplasms-and-qanda monthly 0.9 2025-08-05T14:00:00.000Z https://mpn-hub.com/medical-information/how-might-luspatercept-benefit-patients-with-myelofibrosis monthly 0.9 2024-09-12T11:28:00.000Z https://mpn-hub.com/medical-information/reconsidering-the-place-of-bmt-bmt-reporting-consistency-and-qanda monthly 0.9 2025-08-05T14:00:00.000Z https://mpn-hub.com/medical-information/visual-abstract-or-rop-et-ropeginterferon-alfa-2b-for-et-with-limited-treatment-options monthly 0.9 2024-07-10T10:04:00.000Z https://mpn-hub.com/medical-information/impact-of-allo-hsct-on-survival-outcomes-in-acceleratedblast-phase-mpn monthly 0.9 2024-07-02T10:43:00.000Z https://mpn-hub.com/medical-information/avapritinib-for-the-treatment-of-advsm-latest-updates-from-the-pathfinder-study monthly 0.9 2024-07-02T11:01:00.000Z https://mpn-hub.com/medical-information/ropeg-alfa-2b-on-jak2v617f-allele-burden-molecular-response-and-efs-in-early-pv monthly 0.9 2024-08-07T14:12:00.000Z https://mpn-hub.com/medical-information/eha-2024 monthly 0.9 2024-07-31T09:07:00.000Z https://mpn-hub.com/medical-information/guidance-for-management-strategies-in-early-myelofibrosis monthly 0.9 2024-08-13T09:53:00.000Z https://mpn-hub.com/medical-information/allo-hsct-for-the-treatment-of-pediatric-myelofibrosis monthly 0.9 2024-06-20T08:51:00.000Z https://mpn-hub.com/medical-information/splenic-irradiation-prior-to-hct-to-reduce-relapse-risk-in-patients-with-mf monthly 0.9 2024-05-20T08:20:00.000Z https://mpn-hub.com/medical-information/atypical-variants-of-driver-genes-in-ph-negative-mpn monthly 0.9 2024-05-17T09:32:00.000Z https://mpn-hub.com/medical-information/reveal-elevated-wbc-count-and-thrombotic-events-in-pv monthly 0.9 2024-05-13T09:51:00.000Z https://mpn-hub.com/medical-information/what-novel-therapies-are-under-investigation-for-the-treatment-of-high-risk-mpn monthly 0.9 2024-05-03T10:21:00.000Z https://mpn-hub.com/medical-information/parsaclisib-in-patients-with-mf-and-suboptimal-ruxolitinib-response monthly 0.9 2024-05-10T08:25:00.000Z https://mpn-hub.com/medical-information/qol-in-mpn-physical-psychological-and-social-impacts monthly 0.9 2024-05-01T15:43:00.000Z https://mpn-hub.com/medical-information/freedom2-efficacy-and-safety-of-fedratinib-vs-bat-in-relapsedrefractory-mf monthly 0.9 2024-05-01T15:47:00.000Z https://mpn-hub.com/medical-information/treosulfan-vs-busulfan-based-conditioning-regimens-in-allo-hsct-for-patients-with-mf-an-ebmt-study monthly 0.9 2024-05-01T15:47:00.000Z https://mpn-hub.com/medical-information/ruxolitinib-adherence-in-patients-with-mf-or-pv monthly 0.9 2024-05-01T15:48:00.000Z https://mpn-hub.com/medical-information/transplant-in-patients-mf-the-next-best-approach-after-matched-donor-allo-hsct monthly 0.9 2025-05-28T14:17:00.000Z https://mpn-hub.com/medical-information/rates-of-childbirth-amongst-women-with-myeloproliferative-neoplasms monthly 0.9 2024-05-01T15:49:00.000Z https://mpn-hub.com/medical-information/a-case-series-of-allo-hsct-in-patients-with-mf-and-svt monthly 0.9 2024-05-01T15:49:00.000Z https://mpn-hub.com/medical-information/survival-outcomes-in-patients-with-mf-undergoing-transplantation-role-of-comorbidities-and-bmi monthly 0.9 2024-05-01T15:50:00.000Z https://mpn-hub.com/medical-information/frequency-of-thromboembolic-and-mortality-events-in-patients-with-et-and-pv monthly 0.9 2024-05-01T15:50:00.000Z https://mpn-hub.com/medical-information/revive-trial-updated-results-investigating-efficacy-and-safety-of-rusfertide-in-patients-with-pv monthly 0.9 2024-05-01T15:51:00.000Z https://mpn-hub.com/medical-information/zgjak002-trial-efficacy-and-safety-of-jaktinib-in-patients-with-mf monthly 0.9 2024-05-01T15:52:00.000Z https://mpn-hub.com/medical-information/role-of-red-cell-mass-evaluation-in-patients-with-mpn-and-svt monthly 0.9 2024-05-01T15:52:00.000Z https://mpn-hub.com/medical-information/clinical-trial-club-or-treatment-sequencing-for-anemic-myelofibrosis-qanda-session monthly 0.9 2024-03-15T11:34:00.000Z https://mpn-hub.com/medical-information/clinical-trial-club-or-optimal-treatment-sequencing-and-ongoing-clinical-trials-in-anemic-myelofibrosis-highlights monthly 0.9 2024-03-15T11:32:00.000Z https://mpn-hub.com/medical-information/clinical-trial-club-or-optimal-treatment-sequencing-in-anemic-mf monthly 0.9 2024-03-15T11:30:00.000Z https://mpn-hub.com/medical-information/clinical-trial-club-or-current-clinical-landscape-in-anemic-myelofibrosis monthly 0.9 2024-03-15T11:28:00.000Z https://mpn-hub.com/medical-information/myelofibrosis-neutrophil-to-lymphocyte-ratio-impact-on-prognosis-and-discontinuation-of-ruxolitinib monthly 0.9 2024-05-01T15:52:00.000Z https://mpn-hub.com/medical-information/zinpentraxin-alfa-treatment-for-patients-with-mf-intolerant-of-or-ineligible-for-ruxolitinib monthly 0.9 2024-05-01T15:53:00.000Z https://mpn-hub.com/medical-information/how-do-tp53-mutations-impact-survival-in-patients-with-mpn monthly 0.9 2024-02-20T10:34:00.000Z https://mpn-hub.com/medical-information/splanchnic-vein-thrombosis-impact-on-survival-outcomes-in-younger-patients-with-pv-or-et monthly 0.9 2024-02-19T11:12:00.000Z https://mpn-hub.com/medical-information/one-thousand-patients-with-et-patient-characteristics-management-and-clinical-outcomes monthly 0.9 2024-05-01T15:53:00.000Z https://mpn-hub.com/medical-information/primary-myelofibrosis-prognostic-impact-of-non-driver-mutations monthly 0.9 2024-05-01T15:53:00.000Z https://mpn-hub.com/medical-information/blast-reduction-strategies-for-patients-with-acceleratedblast-phase-myeloproliferative-neoplasms monthly 0.9 2024-02-14T12:07:00.000Z https://mpn-hub.com/medical-information/incidence-of-blast-phase-disease-in-myelofibrosis-according-to-anemia-severity monthly 0.9 2024-02-09T17:38:00.000Z https://mpn-hub.com/medical-information/gut-microbiota-differences-in-mpn monthly 0.9 2024-02-05T16:48:00.000Z https://mpn-hub.com/medical-information/pregnancy-and-mpn monthly 0.9 2024-07-11T10:04:00.000Z https://mpn-hub.com/medical-information/timeline-of-key-drug-approvals-in-mpn-treatment monthly 0.9 2024-07-11T10:04:00.000Z https://mpn-hub.com/medical-information/polycythemia-vera-disease-and-treatment-overview monthly 0.9 2024-07-11T10:02:00.000Z https://mpn-hub.com/medical-information/essential-thrombocythemia-disease-and-treatment-overview monthly 0.9 2024-07-11T10:02:00.000Z https://mpn-hub.com/medical-information/myelofibrosis-disease-and-treatment-overview monthly 0.9 2024-07-11T10:02:00.000Z https://mpn-hub.com/medical-information/myeloproliferative-neoplasms-disease-overview monthly 0.9 2024-07-11T10:02:00.000Z https://mpn-hub.com/medical-information/incidence-and-risk-factors-of-hemorrhagic-events-in-essential-thrombocythemia monthly 0.9 2024-02-02T16:12:00.000Z https://mpn-hub.com/medical-information/tamarin-trial-tamoxifen-for-the-treatment-of-mpn monthly 0.9 2024-01-31T11:37:00.000Z https://mpn-hub.com/medical-information/impact-of-thrombosis-on-disease-progression-and-mortality-in-polycythemia-vera monthly 0.9 2024-01-24T10:45:00.000Z https://mpn-hub.com/medical-information/bms-986158-in-combination-with-jaki-an-early-analysis-of-disease-modification-in-myelofibrosis monthly 0.9 2024-01-23T15:04:00.000Z https://mpn-hub.com/medical-information/mylox-1-trial-loxl2-inhibition-for-the-treatment-of-mf monthly 0.9 2024-01-18T11:26:00.000Z https://mpn-hub.com/medical-information/ebmteln-updated-recommendations-for-allo-hsct-in-myelofibrosis monthly 0.9 2024-01-17T17:23:00.000Z https://mpn-hub.com/medical-information/what-are-some-of-the-promising-new-drugs-in-mpn-therapy monthly 0.9 2024-01-17T11:04:00.000Z https://mpn-hub.com/medical-information/daliah-final-analysis-pegylated-ifna-2-vs-hydroxyurea monthly 0.9 2024-01-15T11:25:00.000Z https://mpn-hub.com/medical-information/selinexor-ruxolitinib-in-jak-naive-patients-long-term-follow-up-from-the-xport-mf-034-study monthly 0.9 2024-01-10T17:42:00.000Z https://mpn-hub.com/medical-information/can-ruxolitinib-replace-hydroxyurea-as-a-frontline-therapy-for-polycythemia-vera monthly 0.9 2024-01-08T12:01:00.000Z https://mpn-hub.com/medical-information/manifest-2-pelabresib-ruxolitinib-for-the-treatment-of-jaki-naive-mf monthly 0.9 2025-03-25T14:08:00.000Z https://mpn-hub.com/medical-information/transform-1-key-safety-and-efficacy-results monthly 0.9 2023-12-21T11:14:00.000Z https://mpn-hub.com/medical-information/real-world-clinical-characteristics-of-post-et-and-post-pv-mf monthly 0.9 2023-12-11T10:49:00.000Z https://mpn-hub.com/medical-information/current-combination-therapies-in-mpn monthly 0.9 2023-12-13T14:56:00.000Z https://mpn-hub.com/medical-information/novel-mpn-therapies-single-agents-beyond-janus-kinase-inhibitors monthly 0.9 2023-12-13T14:56:00.000Z https://mpn-hub.com/medical-information/artificial-intelligence-a-machine-learning-model-for-disease-assessment-in-mpn monthly 0.9 2023-12-06T12:23:00.000Z https://mpn-hub.com/medical-information/cumulative-thrombotic-risk-between-calr1-calr2-and-jak2v617f-mutations-in-et monthly 0.9 2023-12-05T12:20:00.000Z https://mpn-hub.com/medical-information/the-role-of-ai-in-the-future-of-mpn-bone-marrow-histopathology monthly 0.9 2025-08-05T14:03:00.000Z https://mpn-hub.com/medical-information/ash2023-abstracts-what-s-hot-in-mpn monthly 0.9 2023-12-04T17:12:00.000Z https://mpn-hub.com/medical-information/thrombotic-and-hemorrhagic-complications-in-mpn monthly 0.9 2025-08-05T14:04:00.000Z https://mpn-hub.com/medical-information/utilizing-machine-learning-to-predict-thrombosis-in-polycythemia-vera monthly 0.9 2023-11-23T11:57:00.000Z https://mpn-hub.com/medical-information/what-are-the-current-treatment-options-for-intermediatehigher-risk-patients-with-myelofibrosis monthly 0.9 2023-11-24T17:16:00.000Z https://mpn-hub.com/medical-information/momelotinib-in-mf-and-thrombocytopenia-momentum-simplify-1-and-simplify-2-subgroup-analysis monthly 0.9 2023-11-22T11:26:00.000Z https://mpn-hub.com/medical-information/manifest-2-trial-update-significant-improvement-in-svr35-and-tss50 monthly 0.9 2023-11-22T14:39:00.000Z https://mpn-hub.com/medical-information/arterial-and-venous-thromboembolic-complication-risks-in-patients-with-myeloproliferative-neoplasms monthly 0.9 2023-11-10T09:54:00.000Z https://mpn-hub.com/medical-information/myelofibrosis-current-combination-therapies-for-jaki-naive-patients monthly 0.9 2023-10-26T11:53:00.000Z https://mpn-hub.com/medical-information/mdsmpn-diagnostic-differences-between-who-5th-edition-and-icc-schemes monthly 0.9 2023-10-25T15:59:00.000Z https://mpn-hub.com/medical-information/what-are-the-management-considerations-for-accelerated-and-blast-phase-mpn monthly 0.9 2023-10-23T15:37:00.000Z https://mpn-hub.com/medical-information/the-role-of-jak2v617f-allele-burden-in-pv monthly 0.9 2023-10-16T13:59:00.000Z https://mpn-hub.com/medical-information/novel-non-jak-inhibitors-for-mf-updates-from-soho-2023 monthly 0.9 2023-10-03T10:12:00.000Z https://mpn-hub.com/medical-information/u-s-fda-fast-tracks-approval-of-mwtx-003-for-the-treatment-of-pv monthly 0.9 2023-09-25T13:21:00.000Z https://mpn-hub.com/medical-information/treatment-options-in-patients-with-myelofibrosis monthly 0.9 2023-09-19T08:57:00.000Z https://mpn-hub.com/medical-information/fda-approves-momelotinib-for-the-treatment-of-patients-with-anemic-myelofibrosis monthly 0.9 2023-09-18T14:04:00.000Z https://mpn-hub.com/medical-information/et-in-adults-60-years-a-multicenter-real-world-study-in-china monthly 0.9 2023-09-12T11:05:00.000Z https://mpn-hub.com/medical-information/event-free-survival-following-treatment-with-ropeginterferon-alfa-2b-in-patients-with-pv monthly 0.9 2023-09-12T10:11:00.000Z https://mpn-hub.com/medical-information/a-real-world-study-of-predictors-of-response-to-hydroxyurea-and-switch-to-ruxolitinib-in-patients-with-polycythemia-vera monthly 0.9 2023-09-04T13:03:00.000Z https://mpn-hub.com/medical-information/luspatercept-for-the-treatment-of-patients-with-anemic-myelofibrosis-qanda-session monthly 0.9 2024-07-11T09:28:00.000Z https://mpn-hub.com/medical-information/luspatercept-compared-with-other-available-therapies-for-mf monthly 0.9 2024-07-11T09:29:00.000Z https://mpn-hub.com/medical-information/characteristics-of-gut-microbiota-in-patients-with-polycythemia-vera-and-the-impact-of-different-treatments monthly 0.9 2023-09-04T13:03:00.000Z https://mpn-hub.com/medical-information/nct03194542-key-efficacy-and-safety-findings monthly 0.9 2024-07-11T09:29:00.000Z https://mpn-hub.com/medical-information/nct03194542-trial-luspatercept-for-the-treatment-of-patients-with-anemic-myelofibrosis monthly 0.9 2024-07-11T09:29:00.000Z https://mpn-hub.com/medical-information/ship-red-cell-distribution-width-as-a-predictor-of-thromboembolic-complications monthly 0.9 2023-08-01T15:01:00.000Z https://mpn-hub.com/medical-information/luspatercept-mechanism-of-action monthly 0.9 2024-07-11T09:29:00.000Z https://mpn-hub.com/medical-information/pv-real-world-patient-characteristics-and-treatment-patterns-in-taiwan monthly 0.9 2023-07-27T13:47:00.000Z https://mpn-hub.com/medical-information/revive-results-from-the-randomized-withdrawal-phase monthly 0.9 2023-07-14T16:26:00.000Z https://mpn-hub.com/medical-information/fda-grants-fast-track-designation-to-selinexor-for-mf-treatment monthly 0.9 2023-10-10T09:40:00.000Z https://mpn-hub.com/medical-information/what-implications-might-the-persist-2-landmark-os-analysis-data-have-on-the-use-of-pacritinib-in-mf monthly 0.9 2024-06-25T15:46:00.000Z https://mpn-hub.com/medical-information/jaktinib-in-mf-updates-from-asco-and-eha-2023 monthly 0.9 2023-07-04T13:55:00.000Z https://mpn-hub.com/medical-information/krt-232-109-navtemadlin-plus-ruxolitinib-in-mf-with-a-suboptimal-ruxolitinib-response monthly 0.9 2023-07-04T10:04:00.000Z https://mpn-hub.com/medical-information/treatment-free-remission-as-a-new-goal-for-patients-with-pv monthly 0.9 2023-07-03T08:29:00.000Z https://mpn-hub.com/medical-information/should-jak2-vaf-testing-be-implemented-as-routine-in-risk-assessment-and-disease-monitoring-in-mpn monthly 0.9 2023-06-30T09:02:00.000Z https://mpn-hub.com/medical-information/freedom-trial-primary-analysis monthly 0.9 2023-06-29T09:14:00.000Z https://mpn-hub.com/medical-information/pacritinib-shows-symptom-and-spleen-response-regardless-of-cytopenias-in-patients-with-mf monthly 0.9 2023-06-20T08:21:00.000Z https://mpn-hub.com/medical-information/momelotinib-vs-fedratinib-safety-in-mf-indirect-treatment-comparison monthly 0.9 2023-06-15T13:18:00.000Z https://mpn-hub.com/medical-information/maternal-and-fetal-risks-in-pregnancy-with-mpn monthly 0.9 2024-07-11T09:40:00.000Z https://mpn-hub.com/medical-information/manifest-trial-update-pelabresib-monotherapy-for-high-risk-hu-refractory-or-intolerant-et monthly 0.9 2023-06-15T13:45:00.000Z https://mpn-hub.com/medical-information/comfort-i-and-ii-trials-post-hoc-analysis monthly 0.9 2023-06-14T08:10:00.000Z https://mpn-hub.com/medical-information/momelotinib-long-term-safety-pooled-analysis-from-momentum-simplify-1-and-simplify-2 monthly 0.9 2023-05-30T08:49:00.000Z https://mpn-hub.com/medical-information/symptomatic-benefit-of-momelotinib-in-patients-with-mf monthly 0.9 2023-05-24T13:36:00.000Z https://mpn-hub.com/medical-information/eha-2023 monthly 0.9 2023-06-12T08:41:00.000Z https://mpn-hub.com/medical-information/eha2023-abstracts-what-s-hot-in-mpn monthly 0.9 2023-06-05T11:41:00.000Z https://mpn-hub.com/medical-information/asco23 monthly 0.9 2023-05-31T10:52:00.000Z https://mpn-hub.com/medical-information/defining-ruxolitinib-failure-and-transition-to-next-line-therapy-in-mf monthly 0.9 2023-06-01T11:39:00.000Z https://mpn-hub.com/medical-information/majic-pv-trial-update-clinical-benefit-of-ruxolitinib-for-the-treatment-of-pv monthly 0.9 2023-05-24T09:11:00.000Z https://mpn-hub.com/medical-information/avapritinib-granted-fda-approval-for-the-treatment-of-indolent-systemic-mastocytosis monthly 0.9 2023-05-23T14:23:00.000Z https://mpn-hub.com/medical-information/pacritinib-for-spleen-volume-reduction-prior-to-allo-hsct-in-patients-with-cytopenic-mf monthly 0.9 2023-05-22T08:12:00.000Z https://mpn-hub.com/medical-information/secreted-mutant-calreticulins-as-rogue-cytokines-in-myeloproliferative-neoplasms monthly 0.9 2025-08-05T14:02:00.000Z https://mpn-hub.com/medical-information/impact-of-tp53-mutations-in-patients-with-mf-undergoing-hsct monthly 0.9 2023-05-15T14:47:00.000Z https://mpn-hub.com/medical-information/new-agents-in-the-mf-therapeutic-landscape monthly 0.9 2025-08-05T14:02:00.000Z https://mpn-hub.com/medical-information/is-transplantation-still-the-only-curative-treatment-for-mf monthly 0.9 2023-04-28T10:30:00.000Z https://mpn-hub.com/medical-information/diagnosis-and-treatment-of-pediatric-patients-with-mpn monthly 0.9 2024-07-11T09:42:00.000Z https://mpn-hub.com/medical-information/ebmt-2023 monthly 0.9 2023-04-19T14:32:00.000Z https://mpn-hub.com/medical-information/visual-abstract-phenotype-and-survival-outcomes-in-black-african-american-patients-with-pmf monthly 0.9 2024-07-11T09:26:00.000Z https://mpn-hub.com/medical-information/current-treatment-experiences-of-ropeginterferon-alfa-2b-for-patients-with-mpn monthly 0.9 2023-04-17T15:12:00.000Z https://mpn-hub.com/medical-information/revive-trial-meets-primary-endpoint-significant-improvements-with-rusfertide-versus-placebo monthly 0.9 2023-04-11T14:39:00.000Z https://mpn-hub.com/medical-information/what-are-the-key-considerations-in-managing-pregnancy-in-mpn monthly 0.9 2024-07-11T09:41:00.000Z https://mpn-hub.com/medical-information/real-life-diagnostic-and-treatment-approaches-for-patients-with-mpn monthly 0.9 2023-03-24T14:26:00.000Z https://mpn-hub.com/medical-information/common-genomic-diagnostic-tests monthly 0.9 2023-03-23T09:44:00.000Z https://mpn-hub.com/medical-information/conditioning-regimens-and-transplant-outcomes-in-mf monthly 0.9 2023-03-16T16:22:00.000Z https://mpn-hub.com/medical-information/effect-of-allo-hsct-and-bm-fibrosis-regression-on-os-in-patients-with-mf monthly 0.9 2023-03-06T17:24:00.000Z https://mpn-hub.com/medical-information/disease-characteristics-and-outcomes-in-pediatric-and-young-adult-patients-with-mpn monthly 0.9 2024-07-11T09:42:00.000Z https://mpn-hub.com/medical-information/when-to-refer-patients-with-mpn-to-clinical-trials-part-ii-patients-with-mf monthly 0.9 2023-03-29T10:34:00.000Z https://mpn-hub.com/medical-information/when-to-refer-patients-with-mpn-to-clinical-trials-part-i-patients-with-etpv monthly 0.9 2023-03-01T15:57:00.000Z https://mpn-hub.com/medical-information/ropeginterferon-alfa-2b-for-the-treatment-of-low-risk-patients-with-polycythemia-vera monthly 0.9 2023-02-24T12:02:00.000Z https://mpn-hub.com/medical-information/how-to-treat-cytopenic-patients-with-mpn monthly 0.9 2023-02-24T12:02:00.000Z https://mpn-hub.com/medical-information/qol-outcomes-for-patients-treated-with-hu-or-ifna monthly 0.9 2023-02-09T12:17:00.000Z https://mpn-hub.com/medical-information/outcomes-following-allo-hsct-in-patients-with-bp-mpn monthly 0.9 2023-02-08T11:58:00.000Z https://mpn-hub.com/medical-information/avapritinib-granted-fda-priority-review-of-snda-for-the-treatment-of-indolent-sm monthly 0.9 2023-01-31T15:34:00.000Z https://mpn-hub.com/medical-information/bm-fibrosis-changes-with-jak-inhibition-in-mf monthly 0.9 2023-01-25T16:58:00.000Z https://mpn-hub.com/medical-information/momentum-trial-updates-from-ash-2022 monthly 0.9 2023-01-10T16:12:00.000Z https://mpn-hub.com/medical-information/jak-inhibition-in-mpn-updates-from-phase-iii-trials-at-ash-2022 monthly 0.9 2022-12-23T10:05:00.000Z https://mpn-hub.com/medical-information/discovery-of-a-new-anti-calr-mutant-monoclonal-antibody-for-the-treatment-of-mpn monthly 0.9 2022-12-21T15:46:00.000Z https://mpn-hub.com/medical-information/can-jak2v617f-vaf-variations-help-predict-clinical-and-survival-outcomes monthly 0.9 2022-12-15T16:53:00.000Z https://mpn-hub.com/medical-information/combination-therapies-in-myelofibrosis-latest-considerations-on-toxicity-management-with-jak-inhibitors monthly 0.9 2024-07-11T09:54:00.000Z https://mpn-hub.com/medical-information/how-can-chromosomal-and-mutation-abnormalities-in-chronic-mpn-inform-clinical-decision-making monthly 0.9 2022-12-15T16:52:00.000Z https://mpn-hub.com/medical-information/novel-approaches-to-reduce-inflammation-in-myeloproliferative-neoplasms monthly 0.9 2022-12-15T16:52:00.000Z https://mpn-hub.com/medical-information/which-patients-with-mf-could-benefit-the-most-from-telomerase-inhibitors monthly 0.9 2022-12-14T11:57:00.000Z https://mpn-hub.com/medical-information/what-is-the-rationale-for-using-bet-inhibitors-to-treat-myelofibrosis monthly 0.9 2022-12-13T13:54:00.000Z https://mpn-hub.com/medical-information/ash-congress-2022 monthly 0.9 2022-12-06T17:13:00.000Z https://mpn-hub.com/medical-information/editorial-theme-meta-analysis-of-the-effectiveness-of-anticoagulant-therapy-in-patients-with-splanchnic-vein-thrombosis monthly 0.9 2022-12-07T14:29:00.000Z https://mpn-hub.com/medical-information/how-do-symptoms-inform-treatment-decisions-in-mpn monthly 0.9 2022-12-07T11:17:00.000Z https://mpn-hub.com/medical-information/ash-2022-abstracts-whats-hot-in-mpn monthly 0.9 2023-02-09T10:05:00.000Z https://mpn-hub.com/medical-information/editorial-theme-pathogenesis-and-management-of-splanchnic-vein-thrombosis-in-mpn monthly 0.9 2022-11-28T10:03:00.000Z https://mpn-hub.com/medical-information/expand-a-phase-ib-clinical-trial-of-ruxolitinib-for-patients-with-mf-and-low-platelet-counts monthly 0.9 2022-11-24T17:04:00.000Z https://mpn-hub.com/medical-information/prognostic-impact-of-a-cytopenic-phenotype-in-myelofibrosis monthly 0.9 2022-11-17T11:23:00.000Z https://mpn-hub.com/medical-information/international-consensus-classification-2022-for-myeloproliferative-neoplasms monthly 0.9 2022-11-16T12:09:00.000Z https://mpn-hub.com/medical-information/what-is-the-use-for-monoclonal-antibodies-in-mpn monthly 0.9 2022-11-11T12:30:00.000Z https://mpn-hub.com/medical-information/mpncoandd-congress-2022 monthly 0.9 2022-11-12T08:48:00.000Z https://mpn-hub.com/medical-information/selinexor-granted-orphan-drug-designation-by-the-european-commission-for-the-treatment-myelofibrosis monthly 0.9 2023-10-10T09:41:00.000Z https://mpn-hub.com/medical-information/irene-g-a-prospective-rct-of-nutritional-support-following-allo-hsct monthly 0.9 2022-10-31T14:10:00.000Z https://mpn-hub.com/medical-information/mpn-congress-2022 monthly 0.9 2022-11-09T17:42:00.000Z https://mpn-hub.com/medical-information/rusfertide-interruption-leads-to-loss-of-therapeutic-benefit-in-patients-with-polycythemia-vera monthly 0.9 2022-10-20T10:23:00.000Z https://mpn-hub.com/medical-information/thrombosis-risk-in-patients-with-secondary-myelofibrosis monthly 0.9 2022-10-18T16:09:00.000Z https://mpn-hub.com/medical-information/measuring-disease-modification-in-mpn-clinical-trials monthly 0.9 2022-10-11T14:59:00.000Z https://mpn-hub.com/medical-information/neonatal-and-maternal-outcomes-in-pregnant-women-with-mpn-a-population-based-swedish-study monthly 0.9 2024-07-11T09:26:00.000Z https://mpn-hub.com/medical-information/distinctive-prognostic-factors-in-patients-with-thrombocytopenic-myelofibrosis monthly 0.9 2022-09-30T11:27:00.000Z https://mpn-hub.com/medical-information/progression-in-myeloproliferative-neoplasms monthly 0.9 2022-10-10T07:47:00.000Z https://mpn-hub.com/medical-information/how-to-understand-and-manage-cytopenic-myelofibrosis monthly 0.9 2022-09-23T14:01:00.000Z https://mpn-hub.com/medical-information/factors-affecting-transplant-outcomes-in-mf monthly 0.9 2022-09-21T13:04:00.000Z https://mpn-hub.com/medical-information/long-term-survival-and-safety-outcomes-with-momelotinib monthly 0.9 2022-09-21T09:50:00.000Z https://mpn-hub.com/medical-information/visual-abstract-or-key-updates-to-the-classification-of-mpn-in-the-5th-who-classification-of-haematolymphoid-tumours monthly 0.9 2024-07-11T09:26:00.000Z https://mpn-hub.com/medical-information/hydroxyurea-and-secondary-malignancies-in-older-patients-with-mpn monthly 0.9 2022-09-16T08:15:00.000Z https://mpn-hub.com/medical-information/real-world-study-identifying-unmet-needs-in-adolescents-and-young-adults-with-mpn monthly 0.9 2024-07-11T09:43:00.000Z https://mpn-hub.com/medical-information/prognostic-value-of-asxl1mut-in-patients-with-pmf-and-smf monthly 0.9 2022-08-17T11:32:00.000Z https://mpn-hub.com/medical-information/clinical-trial-club-navtemadlin-vs-best-available-therapy-in-relapsed-or-refractory-myelofibrosis monthly 0.9 2024-07-11T09:30:00.000Z https://mpn-hub.com/medical-information/the-mpn-genie-r-app-a-quality-of-life-tracking-tool monthly 0.9 2022-10-28T16:08:00.000Z https://mpn-hub.com/medical-information/reveal-trial-updates-from-the-eha-2022-congress monthly 0.9 2022-10-28T16:08:00.000Z https://mpn-hub.com/medical-information/outcomes-in-patients-with-mpn-associated-splanchnic-vein-thrombosis monthly 0.9 2022-11-16T11:00:00.000Z https://mpn-hub.com/medical-information/thrombotic-events-in-mpn-primary-prophylaxis-to-avoid-the-first-arterial-and-venous-events monthly 0.9 2022-07-26T09:36:00.000Z https://mpn-hub.com/medical-information/the-future-of-jak-inhibition-in-myelofibrosis monthly 0.9 2022-07-18T08:14:00.000Z https://mpn-hub.com/medical-information/treatment-sequencing-in-myelofibrosis monthly 0.9 2022-07-18T08:14:00.000Z https://mpn-hub.com/medical-information/visual-abstract-or-manifest-trial-updates-from-the-eha-2022-congress monthly 0.9 2024-07-11T09:27:00.000Z https://mpn-hub.com/medical-information/eha2022-what-are-the-recent-advances-in-mpn monthly 0.9 2022-07-11T10:44:00.000Z https://mpn-hub.com/medical-information/key-challenges-and-best-practice-recommendations-in-pregnant-patients-with-mpn monthly 0.9 2022-07-04T14:10:00.000Z https://mpn-hub.com/medical-information/momentum-trial-updates-from-the-2022-asco-annual-meeting monthly 0.9 2022-09-02T08:53:00.000Z https://mpn-hub.com/medical-information/gene-panel-testing-for-mdsmpn-overlap monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/how-should-we-define-disease-modification-in-mf monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/defining-disease-modification-with-novel-targeted-agents-in-mf monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/best-practice-recommendations-for-the-management-of-mpn-in-pregnant-patients monthly 0.9 2024-07-11T09:41:00.000Z https://mpn-hub.com/medical-information/momentum-how-might-momelotinib-change-the-treatment-for-cytopenic-patients-with-mf monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/eha-hot-topics monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/realism-uk-study-real-world-treatment-patterns-for-myelofibrosis-in-the-uk monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/presence-of-abnormal-karyotypes-in-essential-thrombocythemia-impacts-fibroticleukemic-progression-and-overall-survival monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/essential-thrombocythemia-with-extreme-thrombocytosis-platelets-at-1500-109l monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/eln-2021-guideline-recommendations-for-polycythemia-vera monthly 0.9 2024-07-11T09:58:00.000Z https://mpn-hub.com/medical-information/simplify-1-update-on-momelotinib-for-myelofibrosis monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/what-is-the-role-of-transplant-in-cnl-key-considerations-about-timing-of-transplant-in-cnl monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/chronic-neutrophilic-leukemia-a-2022-update-on-this-rare-disease-and-its-management monthly 0.9 2022-04-07T13:56:00.000Z https://mpn-hub.com/medical-information/factors-predisposing-failure-to-reach-allogeneic-hematopoietic-stem-cell-transplantation-in-patients-with-myelodysplastic-syndromes monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/navitoclax-add-on-to-ruxolitinib-in-patients-with-myelofibrosis-latest-data-from-the-phase-ii-refine-trial monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/healthcare-inequalities-in-bone-marrow-transplants monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/comparing-responses-of-pegylated-interferon-alfa-and-hydroxyurea-in-patients-with-et-and-pv monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/prognostic-model-to-predict-survival-in-mf-after-6-months-of-treatment-with-ruxolitinib-helps-to-identify-candidates-for-second-line-treatment-and-sct monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/fda-grants-accelerated-approval-to-pacritinib-for-treating-cytopenic-mf monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/updates-on-non-jak-inhibitors-for-mf monthly 0.9 2023-10-10T09:41:00.000Z https://mpn-hub.com/medical-information/survival-outcomes-following-allo-hsct-in-patients-with-accelerated-phase-myelofibrosis monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/single-cell-analysis-at-ash-drivers-of-leukemic-transformation monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/visual-abstract-a-study-to-evaluate-the-efficacy-and-safety-of-pemigatinib-incb054828-in-subjects-with-myeloidlymphoid-neoplasms-with-fgfr1-rearrangement-fight-203 monthly 0.9 2024-07-11T09:27:00.000Z https://mpn-hub.com/medical-information/the-transcriptional-impact-of-treatment-with-interferon-alpha-in-calr-mutated-et monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/patient-follow-up-in-myeloproliferative-neoplasms-best-practices-and-myths monthly 0.9 2024-07-11T09:59:00.000Z https://mpn-hub.com/medical-information/momentum-study-of-momelotinib-for-myelofibrosis-meets-primary-endpoint monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/trial-updates-for-rusfertide-ptg-300-in-polycythemia-vera monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/n-glycosylation-is-an-essential-pathway-in-calr-mutant-mpn monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/educational-theme-or-treating-systemic-mastocytosis monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/haploidentical-donor-bloodmarrow-transplantation-with-ptcy-for-chronic-phase-myelofibrosis monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/ash2021-what-are-the-key-highlights-in-mpn monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/which-factors-may-predict-long-term-outcomes-with-ropeginterferon-alfa-2b-for-the-treatment-of-pv monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/clinico-biological-features-and-prognosis-of-patients-with-mdsmpn-u-with-isolated-isochromosome-17q monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/risk-factors-for-thrombotic-events-in-patients-with-pv-and-et monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/ruxolitinib-treatment-pre-during-and-post-transplant-for-patients-with-mf monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/diagnostic-performance-of-epo-and-jak2-mutation monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/educational-theme-or-systemic-mastocytosis-disease-overview monthly 0.9 2024-07-11T09:55:00.000Z https://mpn-hub.com/medical-information/responses-to-mrna-sars-cov-2-vaccines-in-patients-with-mpn-findings-from-two-studies monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/direct-oral-anticoagulant-use-in-patients-with-myeloproliferative-neoplasms monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/persist-trials-pooled-analysis-of-pacritinib-in-patients-with-mf-and-severe-thrombocytopenia monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/how-effective-is-pacritinib-in-managing-symptoms-and-splenomegaly-in-cytopenic-patients-with-mf monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/freedom-trial-how-can-we-manage-aes-associated-with-fedratinib monthly 0.9 2024-07-11T09:56:00.000Z https://mpn-hub.com/medical-information/peri-transplant-ruxolitinib-in-patients-with-myelofibrosis-a-phase-i-trial monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/ash-2021-abstracts-what-s-hot-in-mpn monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/the-real-world-survival-benefit-of-ruxolitinib-for-myelofibrosis monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/the-influence-of-mpn-on-sars-cov-2-infection-mortality-and-thrombotic-events monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/venetoclax-combinations-for-patients-with-accelerated-and-blast-phase-mpns monthly 0.9 2024-07-11T09:54:00.000Z https://mpn-hub.com/medical-information/mepolizumab-approved-by-european-commission-for-the-treatment-of-hypereosinophilic-syndrome monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/redefining-the-diagnostic-criteria-for-bone-marrow-mastocytosis monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/genetic-testing-in-the-diagnosis-and-management-of-patients-with-atypical-myeloproliferative-neoplasms monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/m monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/genetic-testing-in-the-diagnosis-and-management-of-patients-with-bcr-abl1-negative-myeloproliferative-neoplasms monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/recommendations-from-the-european-leukemianet-to-address-unmet-clinical-needs-in-the-management-of-calr-mutated-essential-thrombocythemia monthly 0.9 2024-07-11T09:59:00.000Z https://mpn-hub.com/medical-information/overall-survival-with-imetelstat-versus-best-available-therapy-with-real-world-data-in-patients-with-rr-mf monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/mutation-specific-responses-to-cytoreductive-therapy-in-patients-with-mpn monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/dual-targeting-of-jak2-and-erk12-enhances-clone-control-and-therapeutic-efficacy-in-mpn monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/how-did-newer-prognostic-models-change-treatment-algorithms-in-primary-and-secondary-mf monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/special-populations-in-mpn-pediatric-adolescent-and-young-adults-with-mpn monthly 0.9 2025-05-20T09:34:00.000Z https://mpn-hub.com/medical-information/the-eha-research-roadmap-updates-for-malignant-myeloid-disorders monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/what-are-the-key-considerations-in-the-management-of-mpn-ap monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/mutations-in-jak2-calr-and-mpl-and-the-effect-on-response-to-ifna-in-mpn monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/how-does-genomic-profiling-impact-myeloproliferative-neoplasms monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/implications-of-clonal-hematopoiesis-of-indeterminate-potential-chip-for-mpn monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/clinical-and-molecular-predictors-of-fibrotic-progression-in-patients-with-essential-thrombocythemia-retrospective-cohort-study monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/erbb2-gene-variants-and-the-risk-of-myeloproliferative-neoplasms monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/the-safety-and-efficacy-of-the-four-jak-inhibitors-in-patients-with-myelofibrosis monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/epicovideha-registry-epidemiology-and-outcomes-in-patients-with-hematologic-malignancies-infected-with-covid-19 monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/survival-outcomes-of-fedratinib-for-patients-with-myelofibrosis-jakarta-and-jakarta2-trials monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/severity-of-sars-cov-2-infection-and-the-safety-of-covid-19-vaccination-in-patients-receiving-hsct monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/patient-reported-experiences-with-covid-19-vaccination monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/allogeneic-hematopoietic-stem-cell-transplantation-for-myelofibrosis monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/interim-translational-data-from-the-manifest-phase-ii-study-of-pelabresib-in-myelofibrosis monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/fungal-superinfections-and-covid-19-in-the-icu monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/avapritinib-produces-durable-responses-in-patients-with-advanced-systemic-mastocytosis monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/updates-of-img-7289-bomedemstat-in-treating-myelofibrosis-and-essential-thrombocythemia monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/tyk2-inhibition-for-calr-mutated-myeloproliferative-neoplasms-a-novel-selective-treatment-approach monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/what-are-the-long-term-effects-of-covid-19-in-patients-with-mpn monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/which-gene-mutations-play-a-role-in-predicting-survival-following-jaki-failure monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/momelotinib-improves-transfusion-independence-and-os-in-patients-with-myelofibrosis monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/jakarta-trials-does-fedratinib-provide-a-survival-benefit-in-patients-with-mf monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/comparison-of-gene-expression-profiles-in-mpn-subtypes monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/prognostic-impact-of-asxl1-mutations-on-primary-and-secondary-myelofibrosis-a-fim-study monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/patient-reliance-on-social-media-for-health-information monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/outcomes-of-venetoclax-hma-therapy-in-patients-with-mpn-bp monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/jump-trial-how-do-patients-with-mf-and-lower-grade-fibrosis-benefit-from-ruxolitinib monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/what-do-phase-ii-data-show-about-the-safety-of-imetelstat-in-rr-mf monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/attenuated-responses-to-covid-19-vaccination-in-patients-with-hematologic-malignancies monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/how-does-transfusion-independence-impact-survival-outcomes-with-momelotinib-in-mf monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/which-factors-may-impact-transplantation-outcomes-in-patients-with-mf monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/activated-il-6-signaling-a-novel-therapeutic-target-for-calr-mutated-mpn monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/eha2021-abstracts-what-s-hot-in-mpn monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/mutant-calreticulin-is-dependent-on-zinc-to-drive-constitutive-mpl-activity monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/gene-expression-signature-as-a-risk-stratification-tool-for-patients-with-myelofibrosis monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/fda-biologics-license-application-of-ropeginterferon-alfa-2b-resubmitted-for-the-treatment-of-pv monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/promising-preclinical-data-on-combined-jak-pim-and-cdk46-inhibition-in-mpn monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/covid-19-vaccination-for-hematopoietic-stem-cell-transplant-patients monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/investigating-the-familial-occurrence-of-systemic-and-cutaneous-mastocytosis-in-adults-a-retrospective-cohort-study monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/germline-mutations-in-patients-with-hematologic-malignancies monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/reconstruction-of-cancer-cell-lineage-history-in-patients-with-mpn monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/drss-a-new-disease-risk-stratification-system-for-hematologic-malignancies monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/what-is-the-impact-of-pre-treatment-ruxolitinib-on-patients-with-mf-receiving-allo-hsct-an-ebmt-cmwp-study monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/does-extreme-thrombocytosis-in-patients-with-low-risk-essential-thrombocythemia-increase-the-risk-of-thrombotic-events-and-benefit-from-specific-therapy-a-retrospective-analysis monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/givinostat-in-polycythemia-vera-long-term-safety-and-efficacy monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/editorial-theme-or-the-management-of-relapsedrefractory-myelofibrosis-part-4-investigational-combination-approaches monthly 0.9 2024-07-11T09:54:00.000Z https://mpn-hub.com/medical-information/should-patients-with-myelofibrosis-be-transplanted-before-or-after-ruxolitinib-failure monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/results-of-phase-iii-devent-trial-show-improved-survival-outcomes-with-ruxolitinib-in-u-s-participants monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/nccn-covid-19-vaccination-recommendations-for-patients-with-hematologic-malignancies monthly 0.9 2024-07-11T09:59:00.000Z https://mpn-hub.com/medical-information/reviewing-the-safety-of-jak-inhibitors-for-the-treatment-of-myelofibrosis monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/what-needs-to-be-considered-in-patients-with-mpn-with-covid-19 monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/essential-thrombocythemia-is-associated-with-a-higher-risk-of-thrombosis-during-covid-19 monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/what-are-the-promising-new-agents-for-patients-with-myelofibrosis monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/treatment-outcomes-with-pegylated-interferon-in-young-patients-with-pvet monthly 0.9 2024-07-11T09:44:00.000Z https://mpn-hub.com/medical-information/thiotepabusulfanudarabine-conditioning-regimen-in-myelobrosis monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/what-s-new-for-the-management-of-polycythemia-vera monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/when-would-you-switch-a-patient-with-myelofibrosis-from-ruxolitinib monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/editorial-theme-article-series-on-relapsed-or-refractory-myelofibrosis-part-3-treatment-options-beyond-jak-inhibition monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/how-effective-are-jak-inhibitor-combinations-for-patients-with-myelofibrosis monthly 0.9 2024-07-11T09:54:00.000Z https://mpn-hub.com/medical-information/editorial-theme-article-series-on-relapsed-or-refractory-myelofibrosis-part-2-novel-jak-inhibitors monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/editorial-theme-or-the-management-of-relapsedrefractory-myelofibrosis-jak-failure-and-challenges monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/genetic-determinants-of-leukemic-transformation-in-mpn monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/5-year-results-from-the-proud-pv-and-continuation-pv-studies monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/clinical-factors-associated-with-response-to-ruxolitinib-in-patients-with-myelofibrosis monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/withdrawal-of-ruxolitinib-increases-risk-of-mortality-in-patients-with-myelofibrosis-and-covid-19 monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/when-should-we-give-jak-inhibitors-to-patients-with-mf-in-the-peri-transplant-setting monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/how-should-conditioning-be-performed-before-transplanting-a-patient-with-mf monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/results-from-an-ongoing-phase-ii-study-of-img-7289-bomedemstat-in-patients-with-advanced-mf monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/european-commission-approves-fedratinib-for-the-treatment-of-myelofibrosis monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/ash-2020-practice-changing-abstracts-in-myeloproliferative-neoplasms monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/is-the-hepcidin-mimetic-ptg300-a-promising-treatment-for-therapeutic-phlebotomy-dependent-pv monthly 0.9 2021-02-04T10:44:00.000Z https://mpn-hub.com/medical-information/novel-agents-to-treat-mf-with-suboptimal-response-to-ruxolitinib-combining-ruxolitinib-with-navitoclax-or-krt-232 monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/novel-agents-to-treat-mf-with-suboptimal-response-to-ruxolitinib-long-term-outcome-with-momelotinib monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/what-do-the-preliminary-results-of-the-manifest-trial-say-about-cpi-0610-in-treating-mf monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/ash-2020-highlights-for-polycythemia-vera monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/imbark-phase-ii-study-of-imetelstat-for-rr-myelofibrosis-updates-from-ash-2020 monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/should-we-consider-early-testing-and-treatment-for-driver-mutations-acquired-in-childhood monthly 0.9 2024-07-11T09:42:00.000Z https://mpn-hub.com/medical-information/interferon-therapy-in-the-management-of-myeloproliferative-neoplasms monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/macrophage-abundance-in-the-bone-marrow-of-patients-with-myeloproliferative-neoplasms monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/simplify-1-2-trial-what-is-the-long-term-benefit-of-momelotinib-treatment-in-rr-mf monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/ropeginterferon-alfa-2b-is-effective-and-safe-in-patients-older-than-60-years-with-pv monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/manifest-phase-ii-study-of-ruxolitinib-and-cpi-0610-in-patients-with-myelofibrosis-an-update-from-arms-2-and-3 monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/manifest-study-does-the-bet-inhibitor-cpi-0610-show-synergy-with-ruxolitinib-in-myelofibrosis monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/use-of-integrative-medicine-may-correlate-with-improved-symptoms-and-quality-of-life-in-patients-with-mpn monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/why-does-adding-navitoclax-to-ruxolitinib-induce-responses-in-patients-with-rr-mf monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/whole-genome-sequencing-shows-driver-mutations-can-be-acquired-very-early-in-life monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/genetic-factors-are-more-important-than-disease-activity-for-transplantation-outcomes-in-patients-with-mpn-bp monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/when-can-we-safely-discontinue-interferon-alpha-therapy-in-patients-with-mpn monthly 0.9 2020-12-17T14:28:00.000Z https://mpn-hub.com/medical-information/does-interferon-alpha-prolong-survival-and-prevent-progression-in-patients-with-pv monthly 0.9 2020-12-15T15:26:00.000Z https://mpn-hub.com/medical-information/the-chmp-recommends-approval-of-fedratinib-for-the-treatment-of-myelofibrosis monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/ash-2020-practice-changing-abstracts-for-mpn monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/ruxolitinib-fails-to-provide-clinical-benefit-in-patients-with-covid-19-related-cytokine-storm monthly 0.9 2021-03-11T11:24:00.000Z https://mpn-hub.com/medical-information/combining-interferon-a-and-arsenic-for-the-treatment-of-jakv617f-mutant-mpn monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/reveal-study-what-have-been-the-most-common-causes-of-mortality-for-patients-with-pv monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/risk-of-secondary-malignancies-in-patients-with-mpn monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/prevalence-of-pulmonary-hypertension-in-patients-with-mpn-and-the-associated-risk-factors monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/results-from-a-phase-ii-trial-of-decitabine-and-ruxolitinib-for-patients-with-mpn-apbp monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/molecular-mechanisms-associated-with-leukemic-transformation-of-pv-and-et monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/underlying-mechanisms-in-the-genetic-disposition-of-myeloproliferative-neoplasms monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/risk-of-inflammatory-bowel-disease-in-patients-with-mpn monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/outcomes-of-hsct-in-blast-phase-of-bcr-abl1-mpn-compared-with-de-novo-and-post-mds-aml monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/predicting-transition-in-prefibrotic-myelofibrosis monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/what-do-we-know-about-the-outcome-of-concomitant-mpn-and-covid-19 monthly 0.9 2020-11-06T10:03:00.000Z https://mpn-hub.com/medical-information/predictive-factors-of-mortality-in-patients-with-hematological-malignancies-diagnosed-with-covid-19 monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/covid-19-implications-for-patients-with-myeloproliferative-neoplasms monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/polycythemia-vera-and-essential-thrombocythemia-2021-updates monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/applying-prognostic-models-for-myelofibrosis-in-practice monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/how-would-you-manage-a-young-man-with-polycythemia-vera-and-fatigue monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/how-can-we-predict-and-reduce-the-risk-of-thrombosis-in-a-patient-with-pv monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/ptg-300-receives-orphan-drug-designation-from-ema-for-the-treatment-of-pv monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/mpn-and-depression-what-is-the-link monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/myeloproliferative-neoplasms-thrombosis-and-covid-19 monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/inherited-hematologic-malignancies-predisposition-syndromes monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/advances-in-allogeneic-hsct-for-patients-with-myelofibrosis monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/the-impact-of-jak-inhibitor-use-on-hsct-outcome-in-patients-with-mpn monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/the-practical-use-of-myelofibrosis-genomics-in-a-clinical-setting monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/mepolizumab-granted-approval-by-fda-for-the-treatment-of-hypereosinophilic-syndrome monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/educational-theme-the-role-of-interferon-alpha-in-the-treatment-of-mpn monthly 0.9 2022-11-14T10:20:00.000Z https://mpn-hub.com/medical-information/new-drug-application-nda-for-accelerated-fda-approval-to-be-submitted-for-pacritinib-in-treating-myelofibrosis-with-severe-thrombocytopenia monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/the-microbiome-and-its-effects-on-the-immune-system monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/how-would-you-manage-a-young-woman-with-thrombocytosis monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/in-vitro-assessment-of-bcl-xl-as-a-therapeutic-target-in-philadelphia-negative-mpn monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/fedratinib-has-been-approved-by-health-canada-for-the-treatment-of-myelofibrosis monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/coupling-germline-genetics-to-interferon-alpha-responses-in-polycythemia-vera-treatment monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/dysregulation-of-the-bone-marrow-niche-contributes-to-the-pathogenesis-of-myeloproliferative-neoplasms monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/how-should-genomic-assessment-in-mf-be-performed monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/the-role-of-inflammation-in-mpn-and-its-therapeutic-management monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/how-can-outcome-after-transplant-be-improved-for-patients-with-mpn monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/how-would-you-manage-a-mildly-symptomatic-middle-aged-woman-with-int-1-primary-myelofibrosis monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/use-of-ruxolitinib-in-patients-with-severe-covid-19 monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/what-is-the-news-about-ropeginterferon monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/what-is-the-clinical-value-and-potential-of-momelotinib-for-anemic-patients-with-myelofibrosis monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/should-we-treat-asymptomatic-early-myelofibrosis-with-jaki monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/molecular-characterization-of-patients-with-polycythemia-vera-that-develop-resistance-to-hydroxyurea monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/understanding-the-pathology-of-mpn-the-value-of-in-vivo-and-in-vitro-models monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/ruxolitinib-discontinuation-syndrome-in-patients-with-myelofibrosis monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/targeting-cd123-with-tagraxofusp-in-patients-with-poor-prognosis-following-a-jaki-treatment-or-recent-results-from-a-phase-iii-trial monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/results-from-a-phase-iii-study-demonstrate-benefit-with-mepolizumab-over-placebo-in-patients-with-hypereosinophilic-syndrome monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/genome-wide-sequencing-enables-genetic-distinction-of-mdsmpn-subtypes monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/cxcr4-expression-on-cd34-blood-cells-is-a-predictive-marker-of-outcomes-in-patients-with-primary-myelofibrosis monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/phase-ii-results-from-krt-232-a-first-in-class-mdm2-inhibitor-for-rr-mf-failing-jak-inhibitor-therapy monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/the-long-term-efficacy-of-interferon-alpha-in-targeting-different-driver-mutations-involved-in-mpn monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/review-or-biology-diagnosis-and-treatment-of-myelofibrosis-up-to-date monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/img-7289-bomedemstat-has-been-granted-access-to-the-european-medicines-agency-prime-scheme-for-the-treatment-of-myelofibrosis monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/survival-following-allogeneic-transplantation-in-patients-with-myelofibrosis monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/targeting-pi3k-pathway-with-parsaclisib-when-ruxolitinib-response-is-not-optimal-in-the-treatment-of-myelofibrosis-results-from-a-phase-ii-trial monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/pxs-5505-investigational-new-drug-application-has-been-submitted-to-the-fda monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/update-from-manifest-phase-ii-study-cpi-0610-in-combination-with-ruxolitinib-in-patients-with-myelofibrosis-and-naive-to-jak-inhibitor-treatment monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/european-real-world-data-further-confirm-the-efficacy-of-ruxolitinib-in-patients-with-pv-refractoryintolerant-to-hydroxyurea monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/myelofibrosis-or-fda-grants-an-orphan-drug-designation-for-pxs-5505 monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/results-of-the-phase-ii-trial-low-pv-ropeginterferon-versus-phlebotomy-for-low-risk-pv monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/how-can-we-use-the-microbiome-to-improve-cancer-immunotherapy-and-alleviate-side-effect-such-as-graft-versus-host-disease monthly 0.9 2020-08-26T13:06:00.000Z https://mpn-hub.com/medical-information/real-world-experience-with-ruxolitinib-in-myelofibrosis monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/u-s-fda-grants-orphan-drug-designation-for-ptg-300-for-the-treatment-of-polycythemia-vera monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/trial-update-of-the-manifest-study-of-cpi-0610-in-patients-with-myelofibrosis-from-eha-2020 monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/calreticulin-haploinsufficiency-is-needed-for-the-indication-of-mpn-like-pathology-in-vitro monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/long-term-safety-analyses-of-momelotinib-in-patients-with-myelofibrosis-eha-2020 monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/manifest-study-does-the-bet-inhibitor-cpi-0610-show-synergy-with-ruxolitinib-in-mf monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/do-we-need-new-endpoints-to-assess-spleen-response-in-mpn monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/how-do-you-manage-ruxolitinib-discontinuation-syndrome monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/fedratinib-in-myelofibrosis monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/practice-changing-abstracts-for-mpn-at-eha-2020 monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/should-ropeginterferon-become-soc-for-all-patients-with-low-risk-pv monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/why-should-we-target-mdm2-with-small-molecule-inhibitor-krt-232-in-patients-with-mf monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/the-role-of-the-nlrp3-inflammasome-in-hematological-pathologies monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/fda-accepts-biologics-license-application-of-ropeginterferon-alfa-2b-for-polycythemia-vera monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/what-are-the-factors-guiding-treatment-decisions-for-transplantation-in-mf monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/promising-preclinical-data-on-selective-hdac11-inhibition-and-mpn-improvement monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/ruxolitinib-failure-management-algorithm-for-myelofibrosis-canadian-mpng-consensus monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/increased-a5b1-integrin-adhesion-to-fibronectin-contributes-to-megakaryocytosis-in-primary-myelofibrosis-models monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/final-phase-ii-results-of-the-smac-mimetic-lcl161-for-intermediatehigh-risk-myelofibrosis monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/results-from-the-pac203-phase-ii-trial-pacritinib-dose-recommendation-in-thrombocytopenic-patients-with-mf monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/five-year-follow-up-of-the-response-phase-iii-trial-ruxolitinib-for-polycythemia-vera monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/post-transplant-cyclophosphamide-and-ruxolitinib-as-gvhd-prophylactic-regimen-in-patients-with-primary-or-secondary-myelofibrosis monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/ash-2019-or-protein-arginine-methyltransferase-5-prmt5-inhibition-a-promising-preclinical-target-for-mpn monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/tet2-mutations-predict-thrombotic-risk-in-patients-with-polycythemia-vera monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/ash-2019-or-manifest-phase-ii-results-cpi-0610-beti-for-refractoryintolerant-myelofibrosis monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/review-of-novel-agents-for-myeloproliferative-neoplasms monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/curative-role-of-allogeneic-hematopoietic-stem-cell-transplantation-in-patients-with-myeloproliferative-neoplasm-unclassifiable monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/proud-pv-phase-iii-results-on-ropeginterferon-alpha-2b-for-polycythemia-vera monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/correlating-eukocytosis-with-risk-of-progression-and-thrombosis-in-pv monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/how-to-switch-therapies-in-patients-with-myelofibrosis monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/management-of-thrombocytopenia-in-patients-with-myelofibrosis monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/preventing-thrombosis-with-ruxolitinib-in-polycythemia-vera monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/what-effect-does-idasanutlin-have-on-tp53-mutated-clones-in-patients-with-polycythemia-vera monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/an-introduction-to-the-mpn-hub monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/proud-pvcontinuation-pv-studies-benefits-of-ropeg-ifn-alfa-2b-for-the-treatment-of-pv monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/can-navitoclax-plus-ruxolitinib-induce-clinically-relevant-responses-in-patients-with-myelofibrosis monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/hjmjjdyjhz4 monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/manifest-study-should-cpi-0610-be-used-as-an-add-on-to-ruxolitinib-in-patients-with-advanced-mf monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/ash-2019-or-is-fedratinib-a-safe-and-efficacious-treatment-option-for-patients-with-pmf-and-low-platelet-counts monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/medical-information/ash-2019-or-an-introduction-to-mpn-biology-and-treatment-options monthly 0.9 2022-07-04T10:58:00.000Z https://mpn-hub.com/about-us/louise-niven monthly 0.6 2026-03-10T10:29:00.000Z https://mpn-hub.com/about-us/helen-croxall-1 monthly 0.6 2026-03-10T10:29:00.000Z https://mpn-hub.com/about-us/jen-wilkinson monthly 0.6 2026-03-10T10:29:00.000Z https://mpn-hub.com/about-us/amelia-campbell-warner monthly 0.6 2026-03-10T10:29:00.000Z https://mpn-hub.com/about-us/jennifer-higgins monthly 0.6 2026-02-25T15:01:00.000Z https://mpn-hub.com/about-us/beth-campbell monthly 0.6 2026-03-10T10:31:00.000Z https://mpn-hub.com/about-us/haimanti-mandal monthly 0.6 2026-03-10T10:31:00.000Z https://mpn-hub.com/about-us/dylan-barrett monthly 0.6 2026-03-10T10:31:00.000Z https://mpn-hub.com/about-us/sari-cumming monthly 0.6 2026-03-10T10:31:00.000Z https://mpn-hub.com/about-us/devon-else monthly 0.6 2026-02-25T15:01:00.000Z https://mpn-hub.com/about-us/nathan-fisher monthly 0.6 2026-02-25T15:01:00.000Z https://mpn-hub.com/about-us/amy-hopkins monthly 0.6 2026-02-25T15:01:00.000Z https://mpn-hub.com/about-us/becky-gribbell monthly 0.6 2026-03-20T13:12:00.000Z https://mpn-hub.com/about-us/natasha-fort monthly 0.6 2026-02-25T15:01:00.000Z https://mpn-hub.com/about-us/addy-dullaghan monthly 0.6 2026-02-25T15:01:00.000Z https://mpn-hub.com/about-us/alison-roddam monthly 0.6 2026-02-25T15:01:00.000Z https://mpn-hub.com/about-us/monty-morris monthly 0.6 2026-04-02T14:43:00.000Z https://mpn-hub.com/about-us/abbie-mckillop monthly 0.6 2026-04-02T14:43:00.000Z https://mpn-hub.com/about-us/nathalie-tipler monthly 0.6 2026-04-02T14:43:00.000Z https://mpn-hub.com/about-us/suzanna-de-barra monthly 0.6 2026-04-02T14:43:00.000Z https://mpn-hub.com/about-us/chris-barnes monthly 0.6 2026-04-02T14:43:00.000Z https://mpn-hub.com/contributors/jean-jacques-kiladjian monthly 0.6 2025-04-24T09:03:00.000Z https://mpn-hub.com/contributors/alessandro-m-vannucchi monthly 0.6 2025-04-24T09:31:00.000Z https://mpn-hub.com/contributors/angela-fleischman monthly 0.6 2025-04-24T09:31:00.000Z https://mpn-hub.com/contributors/chloe-james monthly 0.6 2025-04-24T09:31:00.000Z https://mpn-hub.com/contributors/claire-harrison monthly 0.6 2025-04-24T09:31:00.000Z https://mpn-hub.com/contributors/haifa-kathrin-al-ali monthly 0.6 2025-04-24T09:31:00.000Z https://mpn-hub.com/contributors/john-mascarenhas monthly 0.6 2025-04-24T09:31:00.000Z https://mpn-hub.com/contributors/laura-michaelis monthly 0.6 2025-04-24T09:31:00.000Z https://mpn-hub.com/contributors/ruben-a-mesa monthly 0.6 2025-04-24T09:31:00.000Z https://mpn-hub.com/contributors/stefan-n-constantinescu monthly 0.6 2025-04-24T09:31:00.000Z https://mpn-hub.com/contributors/steffen-koschmieder monthly 0.6 2025-04-24T09:31:00.000Z https://mpn-hub.com/contributors/stephane-giraudier monthly 0.6 2025-04-24T09:31:00.000Z https://mpn-hub.com/contributors/tiziano-barbui monthly 0.6 2025-04-24T09:31:00.000Z https://mpn-hub.com/contributors/aaron-gerds-1 monthly 0.6 2025-04-24T09:31:00.000Z https://mpn-hub.com/contributors/francesco-passamonti-1 monthly 0.6 2025-07-09T12:29:00.000Z https://mpn-hub.com/contributors/juan-carlos-hernandez-boluda monthly 0.6 2025-07-09T12:29:00.000Z https://mpn-hub.com/contributors/francesca-palandri-1 monthly 0.6 2025-07-10T15:26:00.000Z https://mpn-hub.com/steering-committees monthly 0.7 2026-04-03T20:17:45.231Z https://mpn-hub.com/about-us monthly 0.7 2026-04-03T20:17:45.231Z https://mpn-hub.com/newsletter monthly 0.7 2026-04-03T20:17:45.231Z https://mpn-hub.com/our-hubs monthly 0.7 2026-04-03T20:17:45.231Z https://mpn-hub.com/contact monthly 0.7 2026-04-03T20:17:45.231Z